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Riassunto 
 
La linea generale su cui si sviluppa il mio progetto di dottorato è la ricerca e 
misurazione quantitativa di biomarcatori, ed è inserito nel più ampio campo 
della diagnostica medica.  
Un biomarcatore è definito in modo chiaro dalla Food and Drug 
Administration statunitense come “una caratteristica che sia oggettivamente 
misurabile e valutabile come indicatore di processi fisiologici o patologici o di 
risposta a trattamento con farmaci”.  
La ricerca moderna ha compiuto passi da gigante negli ultimi decenni, e ad 
un ritmo sempre crescente ha portato ad un’esplosione di metodiche e 
risultati scientifici impensabili anche solo due decenni fa. In particolare lo 
sviluppo di tecniche come la Risonanza Magnetica Nucleare, la Tomografia 
Assiale Computerizzata, la Spettroscopia di Massa oltre ai progressi della 
chimica e dell’informatica hanno accelerato il processo della conoscenza del 
corpo umano e di ciò che può minacciare il suo benessere.  
La ricerca di un marcatore di patologia è in realtà un processo molto ampio, 
che parte dalla conoscenza approfondita iniziale della malattia, partendo 
dalla sua espressione esteriore per poi passare all’identificazione delle 
cause, su cui lavorare per prevenirne gli effetti, talora drammatici. 
L’eziologia di una patologia può essere esteriore od interiore al nostro corpo, 
o addirittura alla loro interfaccia nella particolare fase di vita simbiotica che è 
la gestazione. Diverse concause possono in effetti alterare il delicato 
equilibrio di crescita intrauterino, con il risultato di minacciare il benessere di 
madre e/o feto. Uno di questi effetti può essere il ritardo di crescita 
intrauterino, patologia che nei paesi sviluppati colpisce da uno a tre neonati 
su mille compromettendone il benessere fisico e/o psichico alla nascita e/o 
nella vita futura. La ricerca ci ha fornito i mezzi per studiare questa 
condizione, in particolare nella scoperta dei meccanismi che la causano, 
spesso evidenziati da una presenza alterata di alcune proteine. La 
proteomica differenziale è la metodica per rilevare questo scostamento da 
una condizione fisiologica equilibrata, ed il primo progetto di ricerca di questo 
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periodo di dottorato è stato proprio rivolto a questo: un’analisi proteomica 
differenziale su siero di cordone ombelicale e fluido amniotico alla ricerca di 
biomarcatori di ritardo di crescita intrauterino, una patologia altrimenti detta 
IUGR (Intra Uterine Growth Restriction). 
Nel progetto in questione sono stati analizzati campioni di siero di cordone 
ombelicale e fluido amniotico provenienti da madri al termine della 
gravidanza, per le quali sia stato diagnosticato (si parla di “casi”) o meno 
(“controlli”) un ritardo di crescita intrauterino. Con la tecnica della elettroforesi 
bidimensionale su gel di poliacrilammide (2D-PAGE) la moltitudine di 
proteine presenti nei suddetti campioni è stata dipanata, in modo da 
identificare separatamente le singole proteine sovra- o sottoespresse in caso 
di patologia. Il risultato è stato l’identificazione di 14 proteine uniche nel siero 
e 11 nel cordone ombelicale, concorrenti complessivamente a determinare 
un quadro d’insieme della patologia. Queste proteine sono coinvolte in 
processi alterati nel caso di ritardo di crescita intrauterino, in particolare: 
coagulazione del sangue, pressione sanguigna, difese immunitarie, 
omeostasi di ferro e rame, stress ossidativo. I risultati forniti dall’elettroforesi 
bidimensionale sono stati validati in modo incrociato con un’altra tecnica, il 
Western Blot, applicato su 5 proteine scelte per importanza fisiologica o 
livello di sovra- o sottoespressione. Di particolare spicco nel determinare il 
quadro complessivo di modulazione proteica sono state: transferrina 
(coinvolta nel trasporto di ossigeno nel sangue), kininogeno (coinvolta nei 
processi di coagulazione e di modulazione della pressione sanguigna), 
fibrinogeno (coinvolta nel processo di coagulazione del sangue), 
angiotensinogeno (uno dei soggetti implicati nella regolazione della 
pressione sanguigna) e componente C3 del complemento (complesso 
proteico implicato nella cosiddetta “immunità innata”). 
Ma se la ricerca applicata si avvale di potenti metodiche è perché a monte 
c’è stato un altrettanto importante lavoro di messa a punto delle stesse. 
Questo lavoro è svolto generalmente da équipe che si occupano di diversi 
aspetti del problema da affrontare. Diverse condizioni patologiche sono 
innescate da un’ alterazione di un meccanismo fisiologico in particolare: la 
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comunicazione attraverso la fosforilazione delle proteine, facente parte del 
gruppo delle cosiddette modificazioni post-traslazionali (PTM, Post 
Translational Modifications). Queste sono modificazioni chimiche delle 
proteine nella fase successiva alla loro sintesi ribosomiale, che a valle di una 
serie di passaggi trasforma in una molecola effettiva l’informazione 
potenziale contenuta nel DNA. Alterazioni in questo processo biologico sono 
causa di gravi malattie come cancro, neurodegenerazione e diabete e 
l’avanzamento della tecnologia è lo strumento per approfondirne la 
conoscenza. In particolare gli studi degli scienziati hanno fatto emergere la 
necessità di nuovi materiali per la cattura delle fosfoproteine, soggetti rari in 
un mare di proteine non fosforilate. Allo scopo una tecnologia promettente è 
lo stampo molecolare di polimeri, che sfrutta la molecola oggetto di analisi 
per formare attorno a sé una tasca complementare ad essa, in grado di 
riconoscerla e legarla successivamente quando rimossa dalla matrice stessa. 
Data poi la dimensione nanometrica delle proteine, lavorare sulla stessa 
scala dimensionale favorisce l’efficacia del riconoscimento delle molecole, 
come avviene per l’interazione antigene-anticorpo. L’idea che nasce da 
questa premessa è quindi quella della sintesi e caratterizzazione di 
nanoparticelle stampate molecolarmente per il riconoscimento di 
fosfoproteine e fosfopeptidi: il secondo progetto seguito durante questo 
periodo di dottorato di ricerca. 
La fase sperimentale ha portato a sintetizzare e caratterizzare fisicamente 
nanoparticelle (cioè particelle aventi almeno una dimensione al di sotto dei 
100 nanometri) di copolimeri con 4 ricette diverse, in presenza o meno del 
templato: fosfotirosina protetta all’azoto terminale con 
fluorenilmetossicarbonile (Fmoc). La fase di verifica delle proprietà di legame 
è stata effettuata su una ricetta delle quattro, preparata stavolta con metodo 
standardizzato, ovvero non sotto forma di nanoparticelle. Si è valutata la 
capacità di legare fosfotirosina in sue soluzioni a concentrazione crescente.  
I risultati vedono una tendenza di legame a saturazione nel polimero 
stampato, mentre un accumulo crescente di substrato nel caso del polimero 
non stampato.  
 IV 
 
Ma l’individuazione dei marcatori di patologie è solo una fase del processo 
della diagnosi medica: una volta individuato un marcatore di patologia è 
necessario mettere a punto un metodo di misura dello stesso. Questo 
metodo dovrà essere il più possibile sensibile alle concentrazioni dell’analita 
nel campione in esame e specifico per esso, in modo da non confondere un 
segnale derivante da un fondo di molecole con la sua presenza. Un grosso 
beneficio alla condizione del paziente può anche derivare dalla possibilità di 
misurare l’analita nel luogo dove si trova la persona, attuando così quella che 
si chiama “point of care diagnostics”. A tale scopo esistono delle tecniche 
analitiche che più si prestano alla realizzazione di dispositivi portatili semplici: 
una di queste è la risonanza plasmonica superficiale (Surface Plasmon 
Resonance, SPR). La terza parte del mio periodo di dottorato è stata quindi 
dedicata alla messa a punto di un metodo di rilevazione di un ormone 
peptidico, l’epcidina, sfruttando la suddetta tecnica. L’analita in questione è il 
principale regolatore del metabolismo del ferro, e la realizzazione di una 
metodica analitica sensibile ed efficace per la sua misurazione è considerata 
essere effettivamente necessaria dalla comunità scientifica internazionale. 
I risultati ottenuti in questa parte sperimentale sono stati la creazione di una 
curva di calibrazione per l’epcidina in concentrazioni nel range pato-
fisiologico 1-100ng/mL, una verifica della scarsa interazione del nostro 
sistema di cattura dell’epcidina nei confronti di un suo competitore, una sua 
forma troncata, più la valutazione della costante di affinità dell’analita per il 
legante utilizzato nella cattura, risultata essere 50nM, quindi in linea con 
precedenti misurazioni in soluzione. 
Date le premesse fin qui espresse ritengo che il lavoro da me svolto si 
inserisca in un panorama di grande interesse per il benessere di ognuno di 
noi. Spero solo di aver dato un contributo piccolo ma sensibile all’impulso 
della ricerca, in particolare in Italia. 
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Preface 
 
The general outline of my 3 year PhD period work focuses on the discovery 
and quantification of proteins and peptides of biological relevance. This 
general aim is branched in different research subjects. 
Medical diagnosis is the process of attempting to determine and/or identify a 
possible disease or disorder. Diagnostics has made many steps forward in 
the last decades with the advent and progress of powerful techniques, like 
imaging techniques (NMR, PET), mass spectrometry, bioinformatics and 
genomic tools. Big leaps have been done also specifically in the biochemical 
field, particularly in the identification and quantity evaluation of molecules 
whose presence in human body increases or decreases following a 
pathological condition.  
The Food and Drug Administration (FDA) defines a biomarker as “a 
characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention”. Biomarker discovery is a long 
process which starts from the study of the characteristics of the organism of 
interest. The genomic approach reveals the potential characteristics of the 
organism, subsequently expressed in a protein pattern through the 
transcriptional and translational steps, eventually followed by the post-
translational modifications.  
The “proteome” is defined as the entire wealth of PROTEins expressed by 
the genOME. This is a very kaleidoscopic entity, different from subject to 
subject and different in different stages of life, or in different situations to 
which an organism can be exposed. Proteins are subjected to Post 
Translational Modifications (PTM, e.g. glycosylation, phosphorylation, 
deamydation, splicing) and these runaway modifications often correlate with 
alterations from the normal setup. A proteomic approach takes a picture of a 
particular stage of life of an organism, and permits to compare the different 
general protein patterns in different situations, e.g. from a normal to a 
disease state. 
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Due to the large number of different proteins (thousands in a single cell) and 
their high differential expression (it can span 10 orders of magnitude in 
human blood) a single stage of separation is not enough to analyze them 
singularly. First of all prefractionation techniques to separate different parts of 
a cell (membrane, citosol, nuclei, etc.) or different fractions of a liquid (blood, 
urine, CSF, synovial fluid) are needed to reduce the complexity. Then 
orthogonal techniques have to be applied. These techniques exploit the 
different physical-chemical characteristics of proteins, e.g. molecular mass, 
isoelectric point, hydrophilicity. Nowadays the most established technique to 
take a snapshot of this changing entity is 2D gel electrophoresis (2-DE). 
Other orthogonal techniques are being used as well. MudPIT 
(Multidimensional Protein Identification Technology), for example, combines 
Strong Cation Exchange chromatography (SCX) and Reversed Phase 
chromatography (RP) to separate proteins and peptides in liquid phase on-
line, and has the advantage to be directly interfaced to a mass spectrometer 
(MS) improving sensitivity and resolution. 
Particular fractions of the proteome can be separately analyzed. One 
important case is phosphorylation, the most widespread and studied PTM. 
Also in this case there are most established techniques to selectively catch 
and analyze phosphorylated proteins and peptides, with the aim of 
characterize phosphorylation pathways and find abnormalities in their 
regulation, frequent in many diseases like cancer or neurodegeneration. In 
order to improve our understanding of these networks, with the aim of finding 
new drug targets or biomarkers, improvements at all the analysis levels are 
needed. One critical step is the enrichment of phosphopeptides, not enough 
efficient for a comprehensive covering of this chemically heterogeneous class 
of molecules. 
Once found a protein or peptide of biological value, its relevance as 
biomarker has to be validated on a wide group of subjects. Then its routine 
measurement can be needed in health screenings, possibly carried out with 
fast and cheap methods. Regarding this goal, biosensors can be particularly 
suitable. These are devices made of a bioreceptor molecule, able to bind to 
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or react with the analyte of interest, a transducing system that converts the 
biological event into an electric signal, and the data analysis system, that 
elaborates this signal to show the final parameter(s) to the operator. 
My 3 years PhD period has evolved in this panorama, spanning from the 
biomarkers/drug targets discovery to assays/biosensors development. 
The first  project that I followed exploited proteomic techniques to find 
relevant protein markers for Intrauterine Growth Restriction (IUGR) in 
cordonal blood and amniotic fluid, to shed some light in the pathology 
mechanisms and furnishing a tool for an early diagnosis of the disease.  
I moved then on the production of Molecularly Imprinted Polymers, with the 
final goal of selectively extract phosphopeptides from a peptide mixture and 
thus find alternatives for the grasp of the phosphoproteome.  
Finally I stepped into the biosensors field, focusing my work on the detection 
of hepcidin peptide hormone, the major subject in iron homeostasis in 
vertebrates and marker of iron unbalance diseases.  
All this work has been done keeping fix one idea in my mind: everybody that 
works in this field faces the challenge and has the inspiring aim of improve, 
maybe just a bit and in a not immediately clear way, the health of anybody of 
us. 
The proteomics work discussed in this thesis was carried out in Mass 
Spectrometry and Proteomics lab at the Biotechnology Department of the 
University of Verona (Italy), in collaboration with the Department of 
Environmental Medicine and Public Health and the Department of 
Gynecological Sciences and Reproductive Medicine of Padova (Italy), that 
provided the biological samples. This study was approved by the Ethical 
Committee of Padova University Hospital, after obtaining written informed 
consent from the mothers of the foetuses. 
The work on Molecularly Imprinted Polymers and the development of the 
SPR biosensor was performed in the Biochemical Methodologies and 
Molecular Imprinting Laboratory at the Biotechnology Department of 
University of Verona (Italy) and in Health Department of Cranfield University 
(Bedfordshire, UK). The results obtained are here discussed and evaluated.
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Chapter 1 
 
DISCOVERY OF NEW PROTEIN MARKERS FOR 
INTRAUTERINE GROWTH RESTRICTION 
 
1 Introduction 
Foetus growth is a complex process driven basically by four factors: 
maternal, placental, genetic and external (1). All these factors are intimately 
correlated in determining a harmonic growth of the foetus. An unbalance of 
one or more of them can determine little or bigger alterations in foetus’ 
wellbeing. In modern hospitals foetus growth is monitored throughout the 
pregnancy with several exams at well determined periods of the expected 40 
weeks of gestation. Ecography is the most renowned method, by which 
different metric parameters are measured: head circumference (HC), 
bipariethal diameter (BPD), femur length (FL), abdominal circumference 
(AC), crown-rump length (CRL) and Humerus Length (HL) (figure 1) (2). 
Other routinary exams are cardiotocography (foetus heart beat), eco-doppler 
(evaluation of blood flux from mother to foetus and vice-versa) and mother’s 
urine and blood analysis (biochemical analysis). 
 
 
Figure 1. Foetal segmentation measured through ecography: A) BPD, B) HC, C) AC, D) FL, 
E) HL, F) CRL (Pictures taken from: Carneiro G, Georgescu B, Good S, 
Comaniciu D, IEEE Transactions on Medical Imaging 2008, 27, 1342-1355). 
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The foetus weight is normally estimated through ecographic measurements, 
e.g. AC as single parameter has a good correlation with the weight (2) and  
normally follows a sigmoidal trend, therefore it is more pronounced in the 
middle of the gestational period (figure 2). Customized growth charts made 
on homogeneous populations are available and are used in order to assess 
the normal increase of the foetus weight (3).  
 
Figure 2.  Sigmoidal trend of foetus’ weight increase during the gestational period 
 (Picture taken from: Peleg D, Kennedy CM, Hunter SK. Am Fam 
Physician. 1998 Aug 1;58(2):453-460). 
 
When the weight is less than the 10th customized centile we speak about a 
small for gestational age foetus (SGA). This small size can be physiological, 
i.e. due to factors like parity or altitude that normally reduce the weight, 
otherwise a pathological condition can be present and it has to be carefully 
considered by ostetricians. In this case we speak about intrauterine growth 
restriction (IUGR).  
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The discrimination between SGA and IUGR is normally determined through a 
series of ecographic measurements with 2 weeks of delay: if the growth 
shows an accentuated slowdown a pathological condition is present, and 
actions have to be taken in order to secure the best health condition for the 
foetus and the mother. This condition is in fact related to serious problems for 
the foetus, both perinatally, carrying increased morbidity and mortality, and 
for the adult life bringing metabolic and cognitive deficits (4). Apart the cases 
where hormonal therapy is effective (5) no proven therapy in uterus is 
nowadays available, and a decision has to be taken in letting the foetus grow 
in adverse conditions or program the delivery. This decision is normally taken 
considering the gestational age, that has to be evaluated as more precisely 
as possible (2). Obstetrical management is therefore critical, and subjected to 
law regulation and juridical disputes. In this context legal medicine plays a 
role in ascertain when a not proper obstetrical management was present, 
having consequences as health problems of the foetus and/or the mother (6). 
The growing number of juridical disputes raises the need of a precise 
determination of the period when the pathological condition emerged 
(damage timing) and if it was not seen. This determination can be made a 
posteriori, evaluating the presence of biomarkers in cordonal blood serum or 
amniotic fluid.  
Amniotic fluid (AF), routinely used for prenatal diagnosis, contains large 
amounts of proteins produced by the amnion epithelial cells, foetal tissues, 
foetal excretions, and placental tissues. Additionally, molecules originating 
from maternal circulation are released in the amniotic cavity. The biochemical 
composition of AF is modified throughout pregnancy and its protein profile 
reflects both physiological and pathological changes affecting the foetus and 
the mother (7), (8). Identification of changes in the balance of proteins, 
therefore, may be used to detect a particular type of pathology, or to identify 
a specific genetic disorder. Potential biomarkers in AF have already been 
identified in cases of inflammation and premature rupture of foetal 
membranes (9), (10). 
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Umbilical cord (UC) blood drawn from the doubly clamped umbilical cord at 
delivery reflects the foetal blood compartment. Along these lines, the cord 
blood levels of various growth factors and hormones have been related to 
size at birth by several groups (11), (12). Protein S100B is a recently 
identified UC blood protein able to assess newborn brain damage (13). Other 
established anoxy markers are umbilical cord blood pH, uric acid, cytokines 
and lactate levels in umbilical vein (14), (15). 
The purpose of this project is to investigate the differential protein expression 
levels in UC serum (UCS) and amniotic fluid (AF) in IUGR, to produce 
information on the causes and mechanisms of prenatal disorders and reveal 
possible markers for postnatal complications and disease progression. 
Moreover, as said before, new markers for precision and accuracy 
improvement of damage timing are needed, in order to assess possible 
responsibilities of a not proper obstetrical treatment. 
The chosen experimental technique is two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE), a well established tool for proteomic analysis 
that can be used to compare patterns of protein expression in various 
biological materials under physiological and pathological conditions. MS, in 
association with bioinformatics, provides the tool for the  identification of 
protein spots on 2D-PAGE maps. In the next paragraph this technique will be 
explained in detail. 
 
2 Two-dimensional gel electrophoresis (2D-PAGE)  
In 2D-PAGE proteins in a sample are separated in two dimensions according 
respectively to their isoelectric point (pI) and molecular mass (MW). The 
technique includes sample preparation, protein separation through gel 
electrophoresis, protein detection, digestion of the differentially expressed 
proteins and their identification with MS and bioinformatic tools (figure 3). 
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Figure 3. Workflow of a clinical proteomics analysis, i.e. regarding clinical samples and 
molecular medicine studies. MALDI: Matrix Assisted Laser Desorption Ionization; 
ESI: Electrospray Ionization. 
 
2.1 Sample preparation 
Normally proteins are in a first step extracted from a complex media, like a 
cell culture or a body fluid, and treated to remove impurities like nucleic acids, 
lipids, salts and sugars. This step can be done for example on serum 
samples through acetone precipitation and centrifugation: impurities will be 
mostly present in the supernatant and proteins can be isolated as pellet. 
These are subsequently solubilized in a highly dispersive media, like 7M 
urea, 2M thiourea plus 3% surfactant (e.g. 3[(3-cholamidopropyl) 
dimethylammonium]-1-propanesulfonate, “CHAPS”, a sulfobetainic 
zwitterionic detergent) Tris buffer. In order to remove nucleic acids a 
prolonged centrifugation at high speed (e.g.14000 x g x 40’) is usually 
effective, otherwise the use of  ampholytes can suit the purpose of precipitate 
them, subsequently removed by centrifugation. In order to improve the 
solubilisation, sulfur bridges are broken by using a reducing agent like 
tributhylphosphine (TBP) and –SH groups are prevented to be re-formed 
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through iodoacetamide or acrylamide (AA) blocking. This operation also 
avoids the creation of fake omo and etero-oligomers due to –SH 
recombination (16). 
 
2.2 Protein separation 
The samples are then loaded onto polyacrylamide strips with an immobilized 
pH gradient (IPG strips) and the applied voltage induces proteins to migrate 
depending on their charge, variable along the strip. When they are in a region 
with pH corresponding to their pI they stop due to a null net charge. This first 
separation is furtherly amplified with a second dimension. The IPG strips are 
equilibrated in a solution containing sodium dodecyl sulphate (SDS), which 
binds to proteins proportionally to the number of aminoacidic residues (about 
1 SDS molecule every 2 residues), conferring to every protein a negative 
charge proportional to its molecular weight. The strip is then interfaced on a 
side of a polyacrylamide gel slab through agarose gel bridging. A second 
electrophoretic migration along the gel matrix separates proteins with the 
same pI but different MW. More maps are produced with different samples to 
evaluate the statistical variation, both analytical and biological. 
 
2.3 Detection of proteins 
Protein spots in the gel are then stained to be visualised and therefore 
evaluate protein amounts. A common stain is colloidal Coomassie blue (17), 
while other stains are SyproRuby. RuBPS (both fluorescent) (18) and Silver 
staining (the most sensitive but at the same time difficult to control for not 
reaching an equilibrium in the staining process) (19). Each of these methods 
is compatible with the downstream MS analysis. 
The gel images are then acquired and digitized, to be furtherly analysed with 
dedicated software like PDQuest, Melanie, Phoretic and Progenesis Gel 
images are superimposed to match protein spots, in order to compare 
quantities of the same protein between the gels and find modulations of 
expression between groups of samples. The level of appreciable differential 
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expression depends on the number of replicates, e.g. with 10 replicates a 1.5 
times modulation is appreciable (20). 
 
2.4 Protein digestion 
Once found protein spots with a significant differential expression their 
identity needs to be inferred. MS methods are the most powerful and 
versatile available with this purpose. First of all the protein spots need to be 
cut out from the gel, then they are submitted to proteolytic digestion with an 
enzyme like trypsin, that cleaves peptide bonds in proximity of a C-terminal 
lysine or arginine and generates peptides of suitable length for MS analysis 
(figure 4). 
 
Figure 4. Mass Spectroscopy methods. In proteomics mostly MALDI and ESI methods are 
used to ionise proteins and/or peptides, subsequently fragmented to give a MS
1
 
spectrum. A further fragmentation of the most abundant peptides gives the MS
2
 
spectrum. 
 
2.5 Protein identification 
The identification of proteins through mass spectroscopy relies on the 
accurate measurement of protein and peptide masses. 
A mass spectrometer is a device made essentially of three components:  
1) an ionizing source, that in this case ionizes proteins and peptides;  
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2) a mass analyser, that resolves the ions in dependence of their 
mass/charge ratio (m/z);  
3) a detector, that reveals the ions resolved by the mass analyser.  
In proteomic studies two ionizing methods are generally employed: Matrix 
Assisted Laser Desorption Ionization (MALDI) and Electrospray Ionization 
(ESI) (21). In MALDI peptides are co-crystallized in a matrix with molecules 
like sinapinic acid or alpha-cyano-4-hydroxycinnamic acid. A laser impulse 
then softly desorbs and ionizes the peptides, whose m/z is measured, usually 
with Time-Of-Flight detectors (TOF). The combination of more peptide 
masses is associated with a specific protein (peptide fingerprint). In order to 
deepen the analysis a further fragmentation of peptides can be performed, 
via a second collision chamber and another TOF analyser (MALDI-
TOF/TOF). The collision with helium atoms, electrons or other collision 
agents like electron transferring molecules induces the backbone 
fragmentation in correspondence of peptide bonds, permitting to infer the 
peptide sequence through calculation of mass difference of adjacent peaks 
(tandem MS/MS). 
In ESI-MS, instead, peptides firstly separated with an HPLC column are 
ionised with an electrospray system. The preferred detectors for this system 
are Ion Trap (IT) and triple quadrupole (QQQ). 
The peptide sequence is the first step in protein identification, and its 
reliability is expressed through a score, calculated as S= -10Log10(P). P is the 
probability that a sequence match between MS and database data is a 
random event, and is given by the ratio between the significance threshold of 
random match chosen E and the number of proteins in the database N. 
For example, if during a search 500000 peptides fell within the window of 
mass tolerance chosen and the significance threshold chosen is 0.05 (1 in a 
20 chance to to be a false positive) the corresponding score threshold would 
be S= -10Log10(E/N) -10Log10(0.05/500000)= 70. The protein score is given 
by the sum of the scores of individual peptides.  
Other parameters to be included in mass spectrum analysis are mass 
tolerance, the presence of modifications (e.g. –SH blocking with AA) and the 
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N- or C-terminal aminoacid depending on the lysing enzyme used. The mass 
spectrum is a forest of peaks, and the highest are submitted to further 
fragmentation. The results of fragmentation are analysed with softwares like 
MASCOT (at the Matrix Science server) or SEQUEST to correlate the 
peptide sequences with the ones usually derived from genomic data. These 
data can be found in dedicated protein databases like SWISSPROT 
maintained by the Swiss Institute for Bioinformatics and the European 
Bioinformatics Institute, or the USA government-funded National Center for 
Biotechnology Information (NCBI).  
A successful protein identification depends on many parameters, like the 
number of successfully identified peptides, their uniqueness for a protein and 
the sequence coverage. Nevertheless there can be ambiguities, and a 100% 
assignation is not always possible (that is why mass spectroscopists speak 
about “correlation” and not “identification”) (21). A MASCOT score for a 
peptide above 30 is usually considered enough to have a good correlation. 
 
2.6 Bioinformatics 
Once obtained a reasonable correlation between MS data and a protein, it 
becomes a potential candidate as marker of disease or of drug treatment. In 
order to have a complete understanding of its role, its molecular functions 
(e.g. enzyme), cellular or extracellular districts where it is present (e.g. 
cytoplasma) and biological processes in which it is involved (e.g. glucose 
oxidation) have to be known. This study, called Gene Ontology (GO) can be 
performed with one of the many softwares available, like SWISSPROT or 
GeneCards, curated by the Crown Human Genomic Centre at the Weizmann 
Institute of Science in Israel (22). 
The next step is inserting the protein in the nets of processes in which it is 
involved, this time with the help of dedicated softwares like Kioto 
Encyclopedia of Genes and Genomes (KEGG, hosting more than 150000 
pathway maps) or Reactome. 
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3 Materials and methods 
3.1 Umbilical cord blood and amniotic fluid withdraw  
The study, approved by the Ethical Committee of Padova University Hospital 
(Padova, Italy), was performed after obtaining written informed consent from 
the mothers of the foetuses. Ten IUGR and ten AGA full-term singleton 
neonates, all of Italian origin, were included in the study. Offspring of mothers 
with a birth weight below the 10th customized centile were characterized as 
IUGR. The Gestation Related Optimal Weight  computer-generated program 
was used to calculate the customized centile for each pregnancy, taking into 
consideration significant determinants of birth weight, such as maternal 
height and booking weight, ethnic group, parity, gestational age and gender. 
The choice of the neonates excluded the cases where a chromosomal 
pathology, child-dependent disease or mother consumption of xenobiotics 
were present. 
Umbilical cord blood samples (UCS) have been withdrawn from double 
clamped umbilical cord of singletons, from full-term deliveries performed with 
caesarean section. UCS was obtained after clotting for 30-45 min at room 
temperature followed by centrifugation at 3000g for 20 min in BD 
Vacutainer® glass serum tube, then samples were added of protease 
inhibitors (Roche) and frozen straightaway at -80°C until the analysis. 
Amniotic fluid (AF) samples were obtained through withdrawing with syringe 
after amniotic sac resection, and treated with the same procedure as serum, 
avoiding the clotting step. 
 
3.2 Protein sample preparation 
The samples of UCS were albumin and IgG depleted (with ProteoPrep Blue 
Depletion kit, Sigma). Proteins, from UCS and AF, were precipitated with 4 
volumes of acetone at -20°C for 2 h and then resuspended in a solubilising 
solution: 7 M urea (Sigma, Sigma-Aldrich Corporation, St. Louis, MO, USA), 
2 M thiourea (Sigma), 3% CHAPS (Sigma), and 20 mM Tris (Sigma). 
Centrifugation at 14000 x g at 4°C for 40 min was performed to get rid of 
incidentally present nucleic acids.  
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The samples were then incubated with 5 mM tributylphosphine (Sigma) and 
20 mM acrylamide (Sigma) for 60 minutes at room temperature to reduce 
protein disulphide bonds and alkylate the cysteine thiolic groups. The 
reaction was blocked by the addition of 10 mM ditiothreitol (DTT, Sigma). 
Protein concentration was evaluated by Detergent Compatible (DC) Protein 
assay (Bio-Rad Labs., Hercules, CA, USA) based on the Lowry method. 
 
3.3 Two-dimensional gel electrophoresis and image analysis 
UCS and AF protein fractionation by 2-DE were performed as reported by 
Cecconi el al. (23). Briefly, 450 µl of each sample (containing 3 mg/ml of 
protein) was separated by 17 cm pH 3-10 NL IPG strip, and the total product 
time x voltage applied was 70000 Vh for each strip. The second dimensional 
separation was done using 8-18%T gradient SDS-PAGE, applying 40 mA for 
each gel for 3 min, then 2 mA/gel for 1 h, and 20 mA/gel until the track dye, 
bromophenol-blue, reached the anodic end of the gels. After 2-DE, the 
proteins were detected by Sypro Ruby. The image analysis of the 2D gels 
replicates was performed by PDQuest software (Bio-Rad), version 7.3. Each 
gel was analysed for spot detection, background subtraction and protein spot 
optical density (OD) intensity quantification. The gel image showing the 
higher number of spots and the best protein pattern was chosen as a 
reference template, and spots in this standard gel were then matched across 
all gels. Spot quantity values were normalised in each gel dividing the raw 
quantity of each spot by the total quantity of all the spots included in the 
standard gel. Gels were divided in two groups (control and IUGR samples) 
and, for each protein spot, the average spot quantity value and its variance 
coefficient in each group were determined. Data were log transformed and 
analysed with Student’s t-test, then spots giving significant results (P < 0.01) 
were verified visually to exclude artefacts. 
 
3.4 Mass spectrometry and protein identification 
Spots showing a statistically significant differential expression were carefully 
cut out from 2-D Sypro Ruby stained gels and subjected to in-gel trypsin 
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digestion (17). Briefly, spots were destained with three washing steps: 50mM 
NH4HCO3, 50% 50mM NH4HCO3 (v/v), 50% acetonitrile, 100% acetonitrile, 
and dried at 37°C for 30 min. The gel pieces were then swollen in digestion 
buffer containing 50mM NH4CO3 and 12.5ng/ml of trypsin (modified porcine 
trypsin, Promega, Madison, WI) and the digestion proceded at 37°C 
overnight. The supernatants were collected and peptides were extracted in 
an ultrasonic bath (twice with 50% acetonitrile, 50% H2O v/v with 1% formic 
acid, once with acetonitrile). Finally tryptic peptides were dried by vacuum 
centrifugation. Peptides from 8 μl of each sample were then separated by 
reversed phase (RP) nano-HPLC-Chip technology (Agilent Technologies, 
Palo Alto, CA, USA) online-coupled with a 3D ion trap mass spectrometer 
(model Esquire 6000, Bruker Daltonics, Bremen, Germany). The chip was 
composed of a Zorbax 300SB-C18 (150mm×75m, with a 5m particle size) 
analytical column and a Zorbax 300SB-C18 (40 nL, 5m) enrichment column. 
The complete system was fully controlled by ChemStation (Agilent 
Technologies) and EsquireControl (Bruker Daltonics) softwares. The scan 
range used was from 300 to 1800 m/z. For tandem MS experiments, the 
system was operated with automatic switching between MS and MS/MS 
modes. The three most abundant peptides of each m/z were selected to be 
further isolated and fragmented. The MS/MS scanning was performed in the 
normal resolution mode at a scan rate of 13.000 m/z per second. A total of 
five scans were averaged to obtain an MS/MS spectrum. Database searches 
were conducted using the MS/MS ion search of Mascot against all entries of 
the non-redundant NCBI database with the following parameters: specific 
trypsin digestion, up to one missed cleavage; fixed and variable 
modifications: propionamide (Cys) and oxidation (Met), respectively; peptide 
and fragment tolerances: ± 0.9 Da and ± 0.9 Da, respectively, and peptide 
charges: +1, +2 and +3. For positive identification, the score of the result of  
[- 10 x Log10(P)] had to be over the significance threshold level (P < 0.01) and 
at least 2 different peptides (p < 0.05) had to be assigned. 
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3.5 Protein validation by Western Blot analysis  
Protein samples were precipitated with cold acetone at -20°C for 2 hours and 
centrifuged at 14000xg for 10 min. The pellets obtained were dried and 
resuspended with Laemmli’s sample buffer (62.5 mM Tris-HCl, pH 6.8, 25% 
glycerol, 2% SDS, 0.01% Bromophenol Blue, 5% ß-mercaptoethanol) 
through 5 min heating in boiling water. A 1-D SDS-PAGE separation on 
10%T acrylamide gel in Tris/glycine/SDS buffer was then performed. The 
separated proteins were transferred to a PVDF membrane through 
electroblotting and equal protein loading in each lane (60 g) was verified by 
Ponceau red staining. The membranes were treated with primary and 
secondary antibodies at the appropriate dilutions (see Table 1) and bound 
antibody was detected by Enhanced Chemiluminescence (ECL) Western 
blotting detection system (Millipore, USA). Western blots were scanned by a 
ChemiDoc instrument (Bio-Rad) and images were analyzed using Quantity 
One image processing software (Bio-Rad). 
 
3.6 Classification of Proteins  
Functional annotation was obtained by assignment of Gene Ontology (GO) 
terms for the identified proteins. GO analysis was performed with the help of 
GeneCards database (http://www.genecards.org), classifying each protein 
with respect to its molecular function and biological process in which it is 
involved. 
 
4 Results 
The typical high resolution 2-DE protein pattern of IUGR and control 
neonates, obtained from UCS and AF protein extracts, are reported in figure 
5 and 6. By PDQuest analysis we measured differential protein expression by 
analyzing the 10 biological replica of 2-DE maps obtained for each group.  
A total of 18 and 13 spots (matched across all the replica 2D maps) were 
found to be differentially expressed (P < 0.01) in UCS and AF respectively. 
Spots selected from the differential analysis were subjected to RP-HPLC-
ESI-MS/MS analysis for protein identification.  
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The unique differentially expressed proteins identified were 14 in UCS, and 
11 in AF samples. In Table 1, the successfully identified proteins 
corresponding to up- or down-regulated spots in UCS and AF are shown, 
together with the gene names, the standard spot number (SSP), the 
identification parameters and the indication of their gene ontology (GO) 
annotation (biological process and molecular function). Protein GO 
classification indicate that 21% of proteins are involved in inflammatory 
response, 20% in immune response, while a smaller proportion are related to 
transport, blood pressure, and coagulation. Figure 8 shows as a pie chart the 
distribution of the identified proteins catalogued according to the biological 
process in which they are involved.  
Western Blot analysis, performed to determine the level of expression of five 
candidate proteins (complement C3-alpha chain (C3), serotransferrin (TF), 
kininogen light chain (KNG1), apolipoprotein J (CLU), and angiotensinogen 
(AGT) identified by 2-DE analysis are shown in figure 7. The relative protein 
expression in both samples was normalized through Ponceau Red staining, 
that permits to appreciate the total protein amount. Trends of changes in the 
same direction as those detected in the 2D gel analyses were detected for all 
the proteins. The quantitative difference between the results obtained by 2D 
electrophoresis and by Western Blot suggested that most changes detected 
by the former technique specifically involve post-translationally modified 
forms, which can be only separated in 2D maps (figure 5 and 6). 
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Figure 5. 2D-PAGE map of UCS with spots of differentially expressed proteins pinpointed 
with an SSP (Standard Spot numbering), assigned by PDQuest software).  
 
 
Figure 6. 2D-PAGE map of AF with spots of differentially expressed proteins pinpointed with 
an SSP (Standard Spot numbering), assigned by PDQuest software).   
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Table 1. Identified proteins that are differentially expressed in UCS and AF of IUGR 
newborns through 2-DE. 
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Alpha-1-B-
glycoprotein 
A1BG  AF 2601 gi|69990 85/51.9 5.4/5.6 15 445 30 protein binding crisp-3 binding 
Alpha-2-
macroglobulin 
A2M UCS 4818 gi|177870 125/163.2 5.3/6.0 5 106 2 endopeptidase inhibitor 
complement 
pathway 

Angiotensinogen AGT UCS 1405 gi|532198 55/53.1 4.8/5.8 13 448 23 vasoconstrictor 
Regulation of 
vasoconstriction 

Apolipoprotein J APOA1 UCS 0103 gi|178855 30/48.8 4.3/6.3 2 69 6 phospholipid binding lipid transport 
Carbonic 
anhydrase 1 
CA1 AF 7103 gi|4502517 30/28.8 6.9/6.6 12 356 34 
carbonate dehydratase 
activity 
one-carbon 
metabolic 
process 

Ceruloplasmin CP  AF 4701 gi|1620909 150/115.4 5.5/5.4 9 274 11 ferroxidase activity ion transport 
Complement 
Component C3, 
Chain A 
C3 UCS 7511 gi|78101267 60/71.1 7.2/6.8 14 730 30 endopeptidase inhibitor 
inflammatory 
response 

Complement 
Component 
C3b, Chain B 
C3 UCS 3403 gi|118137965 55/103.9 5.2/5.2 3 122 4 endopeptidase inhibitor 
inflammatory 
response 

Complement 
Component 
C3b, Chain B 
C3 UCS 4403 gi|118137965 55/103.9 5.2/5.2 18 509 19 endopeptidase inhibitor 
inflammatory 
response 

Complement 
Component 
C3c, Chain B 
C3 UCS 8104 gi|78101270 25/21.5 7.3/5.8 7 172 31 endopeptidase inhibitor 
inflammatory 
response 

Complement 
component C4 
C4A UCS 1002 gi|179674 15/192.7 4.2/6.6 3 54 1 endopeptidase inhibitor 
inflammatory 
response 

Complement 
factor B 
CFI AF 6502 gi|291922 65/85.4 6.5/6.5 13 307 12 peptidase 
inflammatory 
response 

Fibrinogen beta 
chain 
FGB AF 5201 gi|2781208 45/37.6 5.8/5.8 7 206 15 protein binding blood coagulation 
Fibrinogen beta 
chain 
FGB UCS 5208 gi|119625341 34/50.4 5.6/8.6 5 202 13 protein binding blood coagulation 
Hemoglobin 
gamma-G 
HBG2 UCS 1003 gi|31725 13/17.0 4.7/5.9 2 132 20 
oxygen transporter 
activity 
oxygen transport 
Hemoglobin 
gamma-G 
HBG2 UCS 2003 gi|183885 13/16.6 5.2/6.4 3 141 28 
oxygen transporter 
activity 
oxygen transport 
Ig kappa 4 light 
chain 
IGKV4-1 UCS 6107 gi|170684576 20/24.1 6.7/6.2 6 124 22 antigen binding immune response 
Ig lambda chain 
V-IV region 
BCRL4 UCS 7103 gi|87901 20/15.5 6.8/7.7 3 123 25 antigen binding immune response 
Ig lambda chain 
V-IV region 
BCRL4 UCS 8104 gi|87901 20/15.5 7.3/7.7 5 97 25 antigen binding immune response 
Ig light chain IGKJ AF 5103 gi|149673887 25/23.4 6.0/7.0 7 186 34 antigen binding immune response 
Keratin, type II 
cytoskeletal 1 
KRT1 UCS 4007 gi|11935049 12/66.0 5.5/8.2 5 141 6 protein binding 
 cytoskeleton 
organization  

Keratin, type II 
cytoskeletal 1 
KRT1 UCS 6106 gi|119395750 27/66.0 6.8/8.2 13 398 17 protein binding 
cytoskeleton 
organization 

Kininogen-1 
isoform 2 
KNG1 UCS 1408 gi|4504893 55/47.9 4.6/6.3 11 333 21 endopeptidase inhibitor 
regulation of 
vasoconstriction 

Serotransferrin TF UCS 6507 gi|4557871 70/77.0 6.6/6.8 12 429 19 ferric iron binding iron ion transport 
Serum albumin ALB AF 1801 gi|28592 150/69.3 5.2/6.0 1 51 2 transport carrier protein 
Serum albumin ALB AF 5402 gi|6013427 60/69.2 6.0/5.9 9 364 15 transport carrier protein 
Serum albumin ALB AF 6106 gi|157830361 30/47.3 6.3/6.0 11 152 9 transport carrier protein 
Serum albumin ALB AF 6304 gi|27692693 55/47.3 6.2/6.0 19 506 30 transport carrier protein 
Serum albumin ALB AF 8101 gi|27692693 30/47.3 7.4/6.0 17 427 22 transport carrier protein 
 
a)
 Spot numbers refer to 2D gels of Figure 5 and 6. 
b) 
Score is –10log10(p), where p is the probability that the observed match is a random event, 
based on the NCBI database using the MASCOT searching program as MS/MS data. 
c)
 Amino acid sequence coverage for the identified protein. 
d) 
Fold of variation in expression in IUGR/C ratio: increased protein (+), decreased protein (-).   
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Figure 7. Protein expression validation with Western blot analysis for five proteins. Film 
images with the relative protein expression were  normalised by Ponceau red 
staining. Film images were captured with GS710 densitometer (Bio-Rad) and 
analysed with Quantity One software to calculate the band intensities (OD). 
 
 
Figure 8. Protein GO categorization. Distribution of the identified proteins according to the 
biological process(es) in which they are involved. GO analysis was performed by 
using GeneCards database. 
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Table 2. The different primary and secondary antibodies used for Western Blot analysis, with 
the corresponding dilutions.  
 
Primary antibody Dilution 
Mouse anti-complement C3B-alpha (Chemicon) 1:1000 
Mouse anti- angiotensinogen  (Abnova) 1:2000 
Mouse anti-transferrin HTF-14 (GeneTex) 1:1000 
Mouse anti-clusterin CLI-9 (GeneTex) 1:2000 
Rabbit anti-kininogen1 (GeneTex) 1:2000 
Secondary antibody Dilution 
Goat anti-mouse IgG, HRP conjugated (Millipore) 1:5000 
Donkey anti-rabbit IgG, HRP conjugated (Amersham) 1:10000 
 
5 Discussion 
The differentially expressed proteins identified in both umbilical cord serum 
and amniotic fluid samples of IUGR and AGA neonates are described and 
discussed in the following paragraphs. 
 
5.1 Coagulation and IUGR 
The association between coagulation disorders and IUGR has already been 
demonstrated by several publications (24), (25), (26). A low grade activation 
of the coagulation system is in fact suggested as one possible factor in the 
pathogenesis of IUGR. Accordingly, it has been reported that heparin 
treatment significantly improved the growth of the growth-restricted foetus 
(27), (28), (29). Among the proteins that play pivotal role in coagulation there 
is fibrinogen, which is converted by thrombin into fibrin to form a clot. 
Interestingly, it has been demonstrated that the G/A polymorphism at position 
- 455 of the beta-fibrinogen gene may enhance the physiological increase in 
fibrinogen levels during pregnancy and thereby predispose to obstetric 
complications (30), (31). In line with these findings, we found that fibrinogen 
was up-regulated in UCS as well as in AF of IUGR samples. 
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Another protein related to coagulation is also alpha 2-macroglobulin (A2M) 
which is a protease inhibitor with both anticoagulant and procoagulant 
properties (it neutralizes alpha-thrombin, plasmin, and activates protein C) 
(32). In some studies A2M has been negatively correlated with birth weight: 
infants with lower birth weight had higher cord serum A2M concentrations as 
compared to those with higher birth weight (33), (34). Our data stand in 
contrast with these findings, indeed we reported a down-regulation of A2M in 
UCS of mothers of IUGR infants. An explanation of this discrepancy may 
depend on the modulation of different PTM-modified isoforms. 
 
5.2 Immune mechanisms and IUGR 
Another mechanism that seems involved in IUGR development is the 
inflammatory response, which interestingly has been linked to the coagulation 
process state (35), (36). Normal pregnancy is associated with increased 
maternal plasma complement components concentration. Complement 
activation may in fact compensate for the decreased adaptive immunity 
observed in normal pregnancy, and is aimed to protect the host (mother 
and/or foetus) from microorganisms and other potential antigens (37), (38). 
The available data on the relationship between complement activation and 
growth retardation appear to be conflicting: some studies have reported that 
complement levels were significantly lower in mothers of SGA infants than in 
controls (39) suggesting that the immunological derangement leads to 
placental lesions and growth restriction. On the contrary, others indicate that 
complement activation is associated with IUGR and other pathologic 
pregnancy outcomes (such as preeclampsia and recurrent spontaneous 
abortions) (40). In particular, it has been reported that C5 (36), as well as 
C3a activation (41), are crucial intermediary events (in the first trimester of 
pregnancy) in the pathogenesis of IUGR. In this study we found that IUGR 
newborns are related to down-regulation of C3, C3b, C3c, C4 complement 
components in UCS, as well as down-regulation of complement factor B in 
AF samples respectively. Our findings emphasize the central role of 
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complement proteins modulation as a key process implicated in poor 
pregnancy outcomes. 
 
5.3 Blood pressure alteration and IUGR 
Pregnancy is a physiological condition characterised by a progressive 
increase of the different components of the renal renin-angiotensin system 
(RAS). RAS is involved not only in the regulation of blood pressure and fluid-
electrolyte homeostasis, but has also a role in the human placenta 
development throughout gestation: angiotensin II for example inhibits human 
trophoblast invasion (42). Alterations in RAS have been already observed in 
IUGR offspring and may play a key role in the aetiology of IUGR 
hypertension (43), (44). Interestingly, it has been reported that maternal and 
foetal angiotensinogen Thr235 genotypes are associated with an increased 
risk of IUGR (45), (46), as well as of preeclampsia. 
which is a medical condition in which hypertension arises in pregnancy (47). 
Here we reported that angiotensinogen is down-regulated in UCS of IUGR 
newborns. Further studies are needed to understand whether the decreased 
angiotensinogen we identified is the Thr235 variant or not, and to prove 
whether the data obtained are consistent with previous reported from other. 
Another protein related to blood pressure control is kininogen, which belong 
to plasma kallikrein-kinin system (KKS) that plays a role not only in blood 
pressure (via modulation of RAS system), but also in inflammation, 
coagulation and pain. Kininogen is a thiol protease that circulate as two 
different isoforms produced by alternative splicing, high molecular weight 
(HK) and low molecular weight kininogen (LK). Cleavage of HK by plasma 
kallikrein results in kininogen heavy chain (63 kD), light chain (58 kD) and 
modified light chain (45 kD). It has been reported that downregulation of 
plasma HK precedes the onset of preeclampsia (20-week gestation) (48). 
In agreement with these observation, we found that the kininogen modified 
light chain (45 kD) was down-regulated in UCS of IUGR newborns. Moreover, 
it has been reported that reduced levels of vasodilator substances, such as 
prostacyclin and kallikrein, may have a causal role in IUGR (49), (50).  
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5.4 Iron and copper homeostasis, oxidative stress and IUGR 
Cu and Fe metabolism are known to be linked and to play a pivotal role 
during pregnancy: transferrin (Tf) is the main protein regulating Fe 
homeostasis, whereas ceruloplasmin (CP) is the major copper-carrying 
protein which acts as a circulating ferroxidase enzyme able to oxidize ferrous 
ions to less toxic ferric forms. Together ceruloplasmin and transferrin act as 
an antioxidative system. Fe deficiency during pregnancy is common and has 
serious consequences both in the short and the long term such as foetal 
growth retardation and cardiovascular problems in the adult offspring. 
Similarly, Cu deficiency, although not so common, also has deleterious 
effects (51), (52). Here we shown that serotransferrin was down-regulated in 
UCS, while ceruloplasmin was decreased in AF of IUGR newborns. 
Several studies have shown a link between altered iron homeostasis and 
growth retardation: a decrease in transferrin receptor 1 has been reported in 
IUGR placentas (53); elevated maternal ferritin was related to an increased 
risk of IUGR (54), while a decrease of serum concentrations of total and 
highly sialylated serotransferrins was detected in severe preeclampsia (55). 
In addition, as concerning copper homeostasis it has been demonstrated that 
in IUGR placentas the level of Cu was significantly reduced (56), and that 
ceruloplasmin levels were decreased in small for dates babies (57), (58).  
 
6 Conclusion 
Our results support the conclusion that the IUGR condition alters the 
expression of proteins some of which are involved in the coagulation process, 
immune mechanisms, blood pressure and iron and copper homeostasis 
control. The identification of proteins, whose expression is altered by IUGR, 
may contribute to improve the understanding of this important clinical 
condition, leading to the individuation of candidate proteins that could be 
further investigated as biomarkers. The real importance of all of these 
candidates require further validation in vitro and in vivo; nevertheless, they 
could represent promising diagnostic targets, and shed a ray of hope for a 
target-oriented therapy of IUGR. 
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Chapter 2 
 
MOLECULARLY IMPRINTED POLYMERS  
FOR PHOSPHOPROTEOMICS 
 
1 Introduction 
The present project is aimed at developing a pre-fractionation approach for 
proteomics based on selective polymeric materials, to be used prior to 
proteome analysis for selecting classes of proteins on the basis on 
homogeneous functional criteria.  
 
2 A particular fraction of the proteome 
Post-translational modifications (PTMs) are covalent processing events that 
change the properties of a protein by proteolytic cleavage or by addition of a 
modifying group to one or more aminoacids. Far from being mere 
“decorations”, PTMs of a protein determine its activity state, localization, 
turnover, and interactions with other proteins. In signaling, for example, 
kinase cascades are turned on and off by the reversibile addition and 
removal of phosphate groups, and in the cell cycle ubiquitination marks 
cyclins for destruction at defined time points (59). 
Other examples of the biological effects of protein modifications are 
attachment of fatty acids for membrane anchoring and association, 
glycosylation for protein half-life, targeting, “cell-cell” and “cell-matrix” 
interactions. Consequently, the analysis of proteins and their PTMs is 
particularly important for the study of the physio-pathology (60). 
 
3 Phosphoproteomics 
3.1 Introduction 
Phosphorylation is the most widespread and studied Post Translational 
Modification (PTM) in proteins (61).  
It is involved in almost all cell functions: metabolism, osmoregulation, 
transcription, translation, cell cycle progression, cytoskeletal rearrangement, 
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cell movement, apoptosis, differentiation, regulation of the signal transduction 
pathways, intercellular communication during the development and 
functioning of the nervous system (62), (63), (64). 
The phosphorylation/dephosphorylation process is regulated by the switch 
kinases/phosphatases. Kinases add a phosphate group to a receptive side 
chain of an aminoacid; phosphatases catalyze instead the hydrolysis of a 
phosphoester bond (65), (66). The effect of the addition or subtraction of a 
phosphate group is the modification of enzymatic activity, protein-protein 
interaction and cellular localization. 
Phosphorylation is not an unique process: often a single protein can display 
more than a single site suitable for the process, often catalyzed by different 
kinases. For example, glycogen synthase contains at least 9 phosphorylation 
sites, and its modulation is performed by at least 5 protein kinases acting on 
different sites of the protein (67). A misregulation of the phosphorylation 
processes can cause severe damage to the cells, leading to diseases like 
cancer, diabetes or neurodegeneration (68), (69). 
The most common kind of phosphorylation in eukaryotes is O-
phosphorylation, on serine, threonine and tyrosine with a ratio of 1800/200/1 
(70), (71). Other sites of phosphorylation can be histidine, lysine, arginine, 
glutamic acid, aspartic acid and cysteine (64), even though are less studied 
due to the lability of the chemical bond and the subsequent necessity to use 
very special techniques to analyse them. 
It is esteemed that 2-4% of eukaryotic genes are associated with kinases and 
phosphatases (there are about 500 kinase and 100 phosphatase genes in 
the human genome) (72), (73), (74). Around 100,000 phosphorylation sites 
may exist in the human proteome, the majority of which are presently 
unknown (75). The importance of studying the phosphorylation was marked 
by the success of the cancer drug Gleevec, the first to inhibit a specific 
kinase, which gave definitely an impulse to the research on kinases and their 
substrates as potential drug targets (72). 
The comprehensive analysis of the protein phosphorylation should include: 
identification of phosphorylated proteins and of their sites of phosphorylation, 
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how these phosphorylations modify the biological activity of the protein and 
kinases and phosphatases involved in the process.  
 
3.2. A delicate analysis 
Working in phosphoproteomics presents a series of hurdles in the analytical 
strategy.  
The first issue concerns the reversible nature of the phosphorylation. The 
study of the phosphoproteins necessitates their isolation from a cell extract or 
a sub-cellular compartment. Subsequently to the cell lysis, however, many 
enzymes like phosphatases become active, determining the degradation of 
the proteins and detachment of phosphate groups from their sites. Also 
kinases can express their action, confusing the picture of which phosphate 
groups are biologically relevant (65). Working at low temperature helps 
significantly in slowing down these processes, but it’s not enough. In order to 
stop the action of these enzymes it is essential to add to the cell extracts a 
specific mix of inhibitors of proteases and phosphatases (76) while to inhibit 
kinases EDTA, EGTA or kinase inhibitors are added. It is also important to 
choose an inhibition mix that doesn’t interfere with the downstream analytical 
methods, like the phospho-specific enrichment methods.  
Another issue relates with phosphoproteins characterization, mostly 
performed through Mass Spectrometry (MS) methods after enzymatic 
digesting. The detection of phosphopeptides (FPs from now on) with MS is 
hampered by the presence of the non phosphorylated partners; moreover, 
the efficiency of ionization is higher for the latter ones, also generally more 
present in the sample (this fact is referred to as “low stoichiometry” of 
phosphorylation). 
It follows that enrichment methods are necessary to extract the 
phosphoproteins or the FPs from the sample. There are various methods to 
choose from, depending to the kind of sample and the aims of the study. 
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3.3.Detection of phosphoproteins 
The detection of phosphoproteins in a sample still relies on optimized 
“classical” methods.  
 
3.3.1 Isotopic labeling of phosphoproteins 
One of the oldest methods used to study phosphoproteins is the metabolic 
labeling with 32P and 33P. It consists in nourishing living cells or organisms 
with substances labeled with these radioactive isotopes which are 
incorporated in the synthesised proteins. Following lysis of the cells, the 
protein population is isolated through 1-DE or 2-DE, visualized on the gels 
with autoradiography or acquired digitally with Phosphorimager systems. This 
method is still largely employed, because of its simplicity and reliability when 
somebody works with alive systems in vitro or in vivo (77). 
A comparison between the performances of 32P and 33P in labeling the 
proteins was made (78), indicating that 33P gives more neat image and higher 
resolution, even though after a longer exposition time, respect 32P. 
Apart from the safety and environmental implications in using radioactive 
isotopes, this method has other drawbacks. First of all it is not compatible 
with some downstream methods, like MS. Furthermore it can only be applied 
on viable cells, since the radioactive isotopes have to be taken from the 
media and metabolized: it cannot be therefore applied on post-mortem 
tissues or biopsies. 
In in vivo studies, cells are incubated with 32P, however the presence of ATP 
reservoirs inside the cells can interfere with the labeling, reducing the 
efficiency of the method (79). Furthermore, 32P is toxic for the cells, and over 
time can cause damages (80). 
In in vitro studies, proteins are incubated with specific kinases in the 
presence of [γ-32P]-ATP and, under specific conditions, the radioactive atom 
is incorporated into aminoacidic residues. Due to the unnatural presence of 
kinase respect the target protein, however, it is frequent the phosphorylation 
of a different target instead of the natural one (promiscuity) (81). 
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3.3.2 Western Blotting employing phosphospecific antibodies 
Western blotting is a quite old technique. It is based on the selective binding 
of an antibody to a protein, transferred from a 1D or 2D gel to a nitrocellulose 
or polyvinylidene difluoride (PVDF) membrane support, and the subsequent 
revealing of the antibody marked spot with some visual method (82). The key 
role is played by the antibody, that should be specific for the protein epitope 
of interest: in this case epitopes are phosphoserine, phosphothreonine and 
phosphotyrosine. The selectivity and affinity characteristics of the antibody 
are of major importance, to perform specific recognition and limit false 
positives. While excellent anti-phosphotyrosine antibodies have been 
developed (e.g. (PY)20, (PY)100 and 4G10 hybridoma clones), better 
antibodies are still needed for phosphoserine and phosphothreonine. 
Antibodies generated against pSer and pThr, in fact, very often necessitate of 
a consensus sequence flanking the phosphoaminoacid; this might be due to 
the lower immunogenicity of pSer/pThr compared to pTyr (83). 
Grønborg et al. performed a test for specificity and reliability of anti-
phosphoserine and anti-phosphothreonine antibodies (70). They made a 
large scale differential analysis of phosphorylated proteins, succeeding in 
identifying phosphorylation sites and FPs not identified with dedicated 
prediction software. The combination of high resolution 2-DE techniques and 
the Enhanced ChemiLuminescence (ECL) system give improved sensitivity 
to the method, i.e. intensification of around 1000 times of the light emitted 
from a spot (84). 
Although Western blotting is an efficient technique to reveal even small 
amount of protein (10-10 mol), its use in quantitative analysis is limited by the 
variability of the amount of proteins that can be transferred to the membrane. 
 
3.3.3 Direct staining of phosphoproteins 
The easiest way to detect phosphoproteins in a sample is the direct staining 
with a phosphospecific dye after a SDS-PAGE gel. Many attempts have been 
done from the 1970’s (85), but all these methods face problems in terms of 
sensibility and of non specificity, e.g. the inability to discriminate between 
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phosphorylated and non phosphorylated proteins or to detect 
phosphotyrosine. Quite recently a novel fluorescent dye has been introduced: 
Pro-Q Diamond. This dye selectively binds to phosphoproteins requiring a 
very simple experimental protocol. The sensitivity of the stain depends on the 
number of phosphorylated residues of the proteins: the detection limit was 16 
ng for pepsin (1 phosphorylated residue) and 2 ng for casein (8 
phosphorylated residues) (86). Thus, the method is very useful for a 
preliminary screening, but still not sufficient for a comprehensive analysis of 
the phosphoproteome.  
The dye is also compatible with MS and with Multiplex Proteomics (MP), i.e. 
detecting simultaneously phosphoproteins and total proteins (e.g. these latter 
stained with SYPRO Ruby dye) on the same 2D gel. The combination of the 
two staining methods permits to distinguish low represented but highly 
phosphorylated proteins from highly represented but poorly phosphorylated 
ones, comparing the results from the two different colorations. 
 
3.3.4 Detection of phosphoproteins employing protein phosphatases 
The presence or absence of a phosphate group on a protein is enough to 
change its pI and subsequently its position in the 1st dimension of a 2D gel. 
That’s why, by employing a phosphatase enzyme, it is possible to modify the 
position of a protein spot on a map and thus determine its nature comparing 
the maps before and after the treatment. Softwares have been also 
developed that can predict the pI shift due to the addition/removal of a 
phosphate group, that can be of 1-2 pH units (87). As an example, Yamagata 
et al. exploited the specific enzymatic activity of k-phosphatase (kPPase) on 
phosphoserine, phosphothreonine, phosphotyrosine and phosphohistidine 
residues to identify novel phosphoproteins in cultured rat fibroblasts (88). 
The methods employing phosphatases, however, are not suitable for 
quantitative analysis, mainly because of the complexity of the analysis and 
the variable efficacy of the enzymatic action. 
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3.4. Selective enrichment of phosphoproteins and FPs 
The identification of the PTM sites on a protein is generally performed by 
using MS approaches. On most occasions, the only enrichment of the sample 
in phosphoproteins followed by protease-specific digestion and MS analysis 
is not sufficient to identify the sites of phosphorylation present (due to the 
general low stoichiometry of the phosphorylation), thus a second enrichment 
step at the FP level is often also required.  
Some commercial kits for phosphoprotein and FP enrichment are available, 
offering ease of use and reproducibility; nevertheless it has been clearly 
demonstrated that the different methods available differ in the specificity of 
isolation and in the set of phosphoproteins and FPs isolated (89), strongly 
suggesting that no single method is sufficient for a comprehensive 
phosphoproteome analysis. Strategies for phospho-specific enrichment are 
shown in fig.1.  
 
Figure 1. Selective enrichment of phosphoproteins and phosphopeptides.  
 
A) Immunoprecipitation: phosphoproteins or phosphopeptides are selectively 
precipitated through the use of appropriate anti-phospho antibodies; at the 
moment only the use of anti-pTyr antibodies has proven to be robust.  
A) IMMUNOPRECIPITATION
B) AFFINITY CHROMATOGRAPHY
IMAC MOAC MIPs
C) CHEMICAL DERIVATISATION
PAC β-ELIMINATION/MICHAEL ADDITION
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B) Affinity chromatography: a resin with immobilized chelated metal or TiO2 
can selectively bind the phosphoric group of peptides and also proteins in 
IMAC (par. 4.2). A combined approach is SIMAC (IMAC + TiO2). An 
alternative technique could be the use of Molecularly Imprinted Polymers 
(MIPs, par.4.10).  
C) Chemical derivatization: the phosphoric group reacts with the aminogroup 
of a tag in PAC or can be subdued to β-elimination and linking of a suitable 
tag through Michael addition (par. 4.11).  
 
3.4.1 Phosphoprotein enrichment by Immunoprecipitation 
Phospho-specific antibodies can be used to selectively immunoprecipitate 
phosphorylated proteins depending on the specificity of the antibody. As for 
Western blotting (see above) anti-phosphotyrosine antibodies are the most 
reliably and widely used in order to enrich tyrosine-phosphorylated proteins 
from complex mixtures. 
After immunoprecipitation (IP) the phosphotyrosine enriched sample can be 
analyzed with different analytical methods such as 1-DE and 2-DE (90).  
Also in this case, variations of protein phosphorylation levels are very difficult 
to characterize unless in combination with a particular protein labeling (Stable 
Isotope Labeling with Aminoacids in Cell culture: SILAC, see par.6.1) with 
stable isotopes (13C or 15N) is used (91). This strategy allowed a quantitative 
and temporal investigation of tyrosine phosphorylation events of proteins 
involved in signaling pathways after stimulation with Epidermal Growth Factor 
(EGF) (92). 
 
3.4.2 Phosphopeptide and phosphoprotein enrichment using 
Immobilized Metal Affinity Chromatography (IMAC) 
IMAC exploits the material formed through chelation of a di-, tri- or tetravalent 
metal by nitrilotriacetic acid (NTA), iminodiacetic acid (IDA) or 
Tris(carboxymethyl)ethylenediamine (TED) immobilized on a solid support, 
like porous silica beads (93). The most commonly used resins make use of 
Fe3+,Ga3+ and Al3+, even though Zn2+ and Zr4+ are used as well (94). 
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This method is routinary employed in FPs enrichment prior to MS analysis, 
nevertheless it has some limits; the most evident is its undesired ability to 
bind acidic peptides. This limitation has been largely surpassed by the 
acidification of the media (to protonate the carboxylic groups) (95) and 
esterification of the carboxylic moieties with methanolic HCl before the 
enrichment step, even if this method introduces complexity due to the 
variable yield of methylation. 
A second limitation is the net bias of the method towards 
monophosphorylated peptides (96). 
The method is particularly effective when used in combination with an 
enrichment step at the protein level. This operation can be carried out with 
methods like IMAC itself, exploiting however a more suitable solid support, 
like sepharose beads. Moreover, secondary interactions have to be reduced, 
e.g. with the use of denaturing conditions (6M urea). The detachment of the 
potentially many phosphate groups from the column imposes instead the use 
of strong eluting buffer as 0.1-0.2 M EDTA (97). 
Other phosphoprotein enrichment methods are phosphotyrosine IP (98), 
Strong Anion eXchange chromatography (SAX) (99), Strong Cation 
eXchange chromatography (SCX) (100) and SDS-PAGE (101). 
 
3.4.3 Metal Oxide Affinity Chromatography (MOAC) 
Metal oxide chromatography (MOAC) employs mainly Ti, Zr or Al oxides, in 
the form of solid or coated beads, as chromatographic media to sequestrate 
FPs. Many different crystalline forms and nanostructured materials have 
been devised (102). 
The first report about the potentialities of these materials regarded the use of 
TiO2-based columns to sequestrate phosphate ions from the water (103).  
In 2004, Pinkse et al. published a paper on the use of this material to bind 
FPs. They devised a 2D-LC-MS online strategy with TiO2 beads 
(Titansphere) as first dimension and RP as second one (104).  
Acidic conditions (pH 2.9) promoted the adhesion of FPs to the first column, 
leaving the non-phosphorylated ones to flow through and to be analysed with 
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nano-LC-RP- MS/MS. Basic conditions (pH 9.0) eluted FPs in a second step. 
The method was tested on a 153kDa homo-dimeric cGMP-dependent kinase, 
promoting the discovery a total of 8 phosphosites, 2 of which were novel. 
Larsen’s group then devised an off-line strategy to bind FPs to a TiO2 
material. The use of additives as 2,5-dihydroxybenzoic acid (DHB), phthalic 
acid or glycolic acid largely reduced the aspecific attachment of acidic 
peptides (105). This technique has been named HAMMOC, for hydroxy acid 
modified metal oxide chromatography. 
A significative advantage of TiO2 is its tolerance towards most buffers and 
salts used in biochemistry and cell biology laboratories. This is one of the 
reasons which made TiO2 so common in large scale phosphoproteomics 
studies (106). Not only titania has been employed as metal oxide for FPs 
enrichment. Natural substitutes can be oxides belonging to the same group. 
For example, ZrO2 microtips have been recently introduced as mean for FPs 
enrichment. This oxide shows a preference towards singly phosphorylated 
FPs, while TiO2 preferentially retains multiply phosphorylated ones (107). 
However, subsequent large-scale studies demonstrated also a lower 
selectivity versus acidic peptides (108), suggesting the necessity of further 
improvements. 
 
3.4.4 Sequential elution from IMAC (SIMAC) 
The identification of multiply phosphorylated peptides has proven to be a 
hard task, mostly because of their difficult ionization and subsequent low 
signal compared to singly- and not-FPs, so to be not selected for the 
subsequent fragmentation in the mass spectrometer.  
To address this issue, in 2007 Martin Larsen’s group presented an analytical 
strategy for sequential elution of mono- and multiphosphorylated peptides. 
The sequential elution from IMAC (SIMAC) exploits the complementary 
characteristics of IMAC and TiO2 in enriching the sample respectively in 
multiply and singly phosphorylated peptides (76). 
In particular, the elution from IMAC in acidic conditions (pH 1.0) enriches the 
sample in mono-FPs, while the basic conditions (pH 11.3) elute subsequently 
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the multi-FPs (109) A further enrichment with TiO2 chromatography is needed 
only in the acidic fraction, because the basic one is enough depleted of non-
FPs. 
The separation of singly and multiply FPs permits then their analysis with 
pdMS3 (phosphorylated directed fragmentation) in optimized settings for each 
group (76). The method was tested on a 120µg whole-cell extract from 
human mesenchimal stem cells (hMSCs) and the results compared with 
those from TiO2 enrichment alone. A total of 716 phosphosites was identified 
with SIMAC, while 350 with TiO2. Moreover the number of multiply 
phosphorylated peptides was significantly increased (74).  
Recently, a new intriguing method for multiply phosphorylated peptides 
enrichment based on polyarginine-coated diamond nanoparticles was 
presented, however it has still to be tested on large scale samples and where 
a low amount of starting material (micrograms) is available (110). 
 
3.4.5 Magnetic beads 
Starting from the TiO2-based chemistry with the idea to find an easier way to 
perform the extraction of FPs, Chen and Chen (111) thought to conjugate the 
properties of magnetic materials  with those of TiO2, coating Fe3O4 
nanoparticles with TiO2 through a silanic bridge. The nanobeads are mixed 
with a tryptic digest, vortexed and captured with a magnet. The captured FPs 
are subsequently analysed through a laser desorption/ionization from the 
inorganic particles and a run in MS. The method was named SALDI-MS, from 
Surface Assisted Laser Desorption/Ionization Mass Spectrometry (112). 
There were subsequent improvements of the method, using for example 
Fe3O4@C@SnO2 core-shell microspheres (the symbol @ means “coated 
by”), with which scientists were able to detect 77 phosphorylation sites in rat 
liver cells (113). 
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3.4.6 Calcium phosphate precipitation (CPP) 
In 1994, Reynolds et al. presented a strategy for FPs enrichment through 
Ca2+ ions and 50% ethanol  precipitation. The precipitated peptides from a 
tryptic digest of casein mostly contained multiple phosphoserines (114). 
Zhang et al. tested the strategy by using calcium chloride (CaCl2), ammonia 
solution (NH3·H2O) and disodium phosphate (Na2HPO4) on a rice embryo 
preparation (46). The dissolved and desalted pellet was then enriched 
through IMAC. In total, 227 non-redundant phosphorylation sites were 
identified, of which 213 on serine residues and 14 on threonine.  
Through phosphate precipitation directly coupled to LC-MS/MS, Qiangwei Xia 
et al. identified 466 unique phosphorylation sites (379 on serine and 87 on 
threonine) in post-mortem Alzheimer disease brain tissue, 70% of which were 
not reported in Phospho.ELM database (115). 
In both studies no tyrosine phosphorylated peptides were identified: it is not 
clear if this is due to the low abundance of these or to the poor selectivity of 
the method. Anyway the method offers the advantage of being rather simple, 
column-free and straightforward. 
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IMAC 
(Immobilized 
Metal Affinity 
Chromatography) 
IDA or NTA on a 
polymer matrix or 
magnetic beads 
with chelated Fe
3+
, 
Ga 
3+
, Al
3+
 or other 
metal cations. 
Binding through 
electrostatic 
interaction 
between 
phosphate  groups 
and metal cations. 
 
protein,  
peptide 
 
H1 stem cells 
proteins, 10 mg 
 
 
SCX- 
IMAC- 
RPLC- 
MS
2
  
(ETD-OT)  
 
 
10844 
phosphosites 
at1% FDR 13720  
 
 
(116) 
 
Proven to be 
effective in 
large scale 
analysis.  
Limited 
capacity and 
specificity, 
directed 
towards 
multiply 
phosphorylated 
peptides, 
affinity for 
acidic peptides 
 
 D.melanogaster 
lysate  
 Kc167,10 mg 
SCX- 
IMAC- 
RPLC- 
MS
2
  
(LTQ-OT) 
phosphosites at 
0.63% FDR 
(117) 
 
MOAC  
(Metal Oxide 
Affinity 
Chromatography) 
TiO2, ZrO2 or 
Nb2O5 as particles 
or layered on a 
Fe3O4 magnetic 
core. Bidentate 
binding between  
metal and 
phosphoric group 
oxigens. 
 
peptide 
 
HeLa lysate 
(amount not 
given) 
 
 
SCX- 
TiO2- 
RP- 
MS
2
 &MS
3
 
(LIT-FT-
ICR) 
 
 
6600 
phosphosites, 
2244 proteins 
at<1%FPR  
 
 
 
(118) 
 
 
Robust and 
chemically 
inert material, 
high capacity 
and fast 
absorption. 
Slow flow 
desorption, 
most effective 
for singly 
phosphorylated 
peptides. 
 K562 lysate, 
400 µg 
 
SCX-
TiO2/Nb2O5-
RP- 
MS
2
  
(MALDI-
TOF) 
622/642/834 
phosphopeptides 
(Ti/Nb/all*) at 
4%FPR 
(119) 
 
 
SCX (Strong 
Cation 
Exchange) 
Ion Exchange 
Chromatography. 
Phosphopeptides 
less retained by 
stationary phase 
due to their higher 
negative charge 
 
peptide 
 
HeLa cell 
lysate,  
300 µg 
 
 
SCX- 
RP-  
LC- 
MS
2
&MS
3
 
(IT) 
 
 
2002 
phosphosites 
 
 
(119) 
 
Coelution with 
other acidic 
peptides. 
Useful as pre-
enrichment 
technique 
 HEK 293 cell  
lysate, 1 mg 
SCX- 
RP- 
LC- 
MS
2
 
(ETD,LIT) 
>5000 unique 
phosphopeptides 
1%FDR 
(120) 
 
SAX (Strong 
Anion Exchange) 
Ion Exchange 
Chromatography. 
Phosphopeptides 
more retained by 
stationary phase 
due to their higher 
negative charge 
 
peptide 
 
Human liver 
protein digest,  
100 µg 
 
 
SAX- 
RPLC- 
MS2&MS3 
(LTQ) 
 
 
274 
Phosphosites at 
0.96% FDR 
 
 
(122) 
 
Useful for 
peptide 
fractionation. 
Useful as pre-
enrichment 
technique  A.thaliana 
membrane 
proteins digest, 
500 µg 
SAX- 
IMAC- 
RPLC- 
MS
2
  
(Q-TOF) 
299 
Phosphopeptides 
(100) 
 
HILIC 
(Hydrophilic 
Interaction 
Chromatography) 
Phosphopeptides 
more retained by 
stationary phase 
due to their higher 
polarity 
 
peptide 
 
HeLa cell 
lysate, 1 mg 
 
 
HILIC- 
RP- 
MS & S2 
(IT) 
 
 
1004 
phosphosites 
  
 
(121) 
 
 
Coelution with 
other acidic 
peptides. 
Useful as pre-
enrichment 
technique  S.cerevisiae 
total protein, 6 
mg 
IMAC- 
HILIC- 
RP- 
HPLC- 
MS
2
  
(LTQ) 
8764 unique 
phosphopeptides,  
2278 proteins 
(122) 
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Chemical 
derivatisation 
Phosphoric group 
directly bound to a tag 
through 
phosphoramidate 
chemistry, diazo 
chemistry or 
oxidation-reduction 
and condensation. 
Alternatively β-
elimination /Michael 
addition can be 
performed. 
 
peptide 
 
D.melanogaster 
Kc 
167 tryptic 
digest, 1.5 mg 
 
 
PAC- 
RP- 
LC- 
MS
2
  
 
535 
phosphosites 
 
 
(123) 
 
 
Modulation of 
peptide 
properties for 
MS 
purposes. 
Reaction 
yield, side 
reactions, 
large amount 
of sample 
required. 
 Jurkat T cells 
lysate (amount 
not reported) 
PAC- 
RP- 
LC- 
MS
2
  
(LTQ) 
79 tyrosine 
phosphoproteins 
(124) 
 
Immunoprecipitation 
Affinity of the 
phosphosite  to the 
antibody 
 
protein,  
peptide 
 
Jurkat T cells 
lysate (amount 
not reported) 
 
 
IP(pY-100 
antibody)-
RP-LC- 
MS
2
 (LCQ-
IT) 
 
 
194 
phosphotyrosine 
sites 
 
 
(125) 
 
 
Mostly 
directed  to 
p-Tyr 
phosphosites 
 HME Cells 
lysate, 4mg 
IP(pY-100 
antibody)-
RP-LC- 
MS
2
 (LTQ-
OT) 
481 
phosphotyrosine 
sites at FDR 1% 
(126) 
 
Table 1. Comparation of enrichment and fractionation methods for phosphopeptides. 
 
*superimposition without redundancies of Ti and Zr detected phosphosites. 
Abbreviations: CID, Collision-Induced Dissociation; DHB, Dihydroxybenzoic acid; ECD, 
Electron Capture Dissociation; ETD, Electron Transfer Dissociation; FDR, False Discovery 
Rate; FPR, False positive rate; FT-ICR, Fourier Transform Ion Cyclotron Resonance; b-HPA, 
b-hydroxypropanoic acid; LIT, Linear Ion Trap; OT, Orbitrap; Q-TOF, Quadrupole-Time-Of-
Flight; RP, Reversed Phase; SCX, Strong Cation Exchange; LTQ, Linear Trap Quadrupole; 
LCQ, Liquid Chromatography Quadrupole; IP, Immunoaffinity Purification. 
 
3.4.7 Ion exchange chromatography (IC) 
The simple enrichment of FPs with IMAC, TiO2 or SIMAC has generally 
proven to be not enough productive when a deep knowledge of the 
phosphoproteome is required (127).  
A fractionation step is also needed. Chromatography techniques based on 
charge interaction, hydrophilic interaction or a combination of both have been 
employed for this purpose (128). 
Anion exchange chromatography exploits the generally higher affinity of FPs 
for the positively charged stationary phase due to the intrinsic high negative 
charge carried by the phosphate group. Strong anion chromatography (SAX) 
has been employed both as fractionating technique before a FPs enrichment 
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step (e.g. with IMAC or TiO2) (129) and also as sole fractionating technique 
before LC-MS/MS.  
Nühse et al. for example identified more than 300 phosphorylation sites in the 
plasma membrane fractions of Arabidopsis thaliana using a SAX + IMAC 
approach (130), while Han and co-workers identified 274 phosphorylation 
sites in human liver tissue extract without the enrichment step. 
A drawback of this method has been reported by Thingholm et al. (66), who 
noted a strong attachment of FPs to the SAX resin, from which they are 
difficultly recovered. 
Its counterpart, strong cation chromatography (SCX), has been largely 
employed as prefractioning technique for proteins and peptides. The 
pioneering work on FPs was carried out by Beausoleil et al. in 2004 (119). 
Tryptic peptides were acidified at pH 2.7, where most of the peptides carry a 
+2 charge due to C-terminal lysine or arginine and the N-terminal 
aminogroup. FPs, instead, carry a reduced charge due to the phosphate 
group, e.g. +1 in monoFPs. The reduced affinity of the resin should therefore 
leaving FPs to flow more easily through the column. This idea was confirmed 
by the results, which brought to the identification of 2000 phosphosites in 
8mg of nuclear extract of HeLa cells lysate. 
Trinidad and co-workers evaluated the efficiency of SCX as prefractionation 
method prior to IMAC to the efficiency of IMAC and SCX alone, finding a 
three-fold increased FPs identification in the combined approach respect both 
methods (99). 
The strength of SCX as prefractioning system was further confirmed by Olsen 
et al., who identified 6600 phosphosites in 2244 proteins in EGF-stimulated 
HeLa cells through SCX + TiO2 (118). In more recent reports 23000 and 
36000 phosphorylation sites have been identified respectively with SCX 
followed by IMAC and TiO2 respectively (131), (127). This remarkable 
increase in number of detected phosphosites is mainly due to instrumental 
and software improvements (128). 
It remains to be assessed if the fractionation/enrichment approach can be 
suitable in samples where a small amount of starting material is available. 
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3.4.8 Hydrophilic Interaction Chromatography  
Hydrophilic interaction chromatography (HILIC) is a separation technique for 
biomolecules (132). The method relies on the interaction of the analytes, e.g. 
peptides, with a neutral stationary phase through hydrogen bonding. They 
are eluted from the column with a decreasingly organic mobile phase 
according to their polarities (hydrophilicity).  
McNulty and Annan introduced this method as prefractionation step before 
IMAC (121). They tested the FPs enrichment capacity of HILIC compared to 
SCX and IMAC alone, as well as the fractionation ability of HILIC before and 
after IMAC treatment. The analysis of 1 mg of tryptic digest of HeLa cells 
evidenced the prefractionation vocation of the method. The use of IMAC prior 
to HILIC gave in fact a high level of nonspecific binding due to not FPs, while 
the reversed approach improved the selectivity for FPs to more than 99%. 
ERLIC (Electrostatic Repulsion - Hydrophilic Interaction Chromatography), or 
Ion Pair normal phase, is a newly developed chromatographic method able to 
enrich and fractionate FPs in a single step (135).  
At pH 2.0 the C-termini and the carboxylic side chains of Asp and Glu are 
neutral, thus the peptides are generally positively charged and are not 
retained by a positively charged stationary phase. The presence of a 
phosphate group, however, reduces the net charge of FPs; this is not enough 
to overcome the overall repulsion for the stationary phase due to the basic 
residues, however an organic mobile phase, e.g. acetonitrile 70%, promotes 
their hydrophilic interaction within the column. The attraction for the column is 
enhanced in multiply phosphorylated peptides.  
Zarei et al. evidenced in fact a higher efficiency of ERLIC compared to SCX 
and HILIC in fractionating multiply phosphorylated peptides (128) more 
retained by the stationary phase. 
In a recent article (134) Xi Chen et al. compared the FPs profiles obtained 
from a HeLa cell lysate by using 4 HPLC methods after a phosphor-
enrichment with IMAC. Even though with any of the four methods (SCX, 
HILIC, ERLIC with volatile and not volatile solvent) 4-5000 peptides could be 
identified, the combination of all the methods gave a total number of 9069 
 38 
 
unique FPs, with a considerable amount of non-overlapping unique FPs. The 
four methods are thus complementary to get a full coverage of the 
phosphoproteome.  
 
3.4.9 Hydroxyapathite (HAP) 
Firstly introduced by Tiselius and co-workers in 1956 (135), hydroxyapathite 
(HAP) chromatography has been very popular until the 1980s, when new 
matrices have been introduced. HAP is a crystalline form of calcium 
phosphate with formula Ca10(PO4)6(OH)2, which binds FPs in virtue of both 
anionic and cathionic interactions. In particular Ca2+ binds phosphoric groups, 
and more strongly than it does with other acidic groups. The binding to the 
matrix is thus proportional to the number of phosphogroups on the peptides 
and can be exploited for a sequential elution of them according to their 
degree of phosphorylation. Mamone et al. (136) exploited this material to 
analyse a tryptic digest of standard proteins. The advantages of HAP are the 
low cost of the material and the possibility to elute stepwise the peptides 
according to the degree of phosphorylation. Yet the system has to be tested 
on more complex biological samples. 
 
3.4.10 Molecularly Imprinted Polymers (MIPs) 
Recently (137), Borje Sellergren’s group has proposed a method for the 
depletion of phosphotyrosine containing peptides based on Molecularly 
Imprinted Polymers (MIPs). FPs imprinting was performed by an epitope 
approach (138), i.e. using a part of the analyte of interest (in this case the N- 
and C-protected phosphotyrosine) as a template to prepare a MIP able to fish 
FPs. The Solid Phase Extraction analysis showed a 18-fold preferential 
retention for phosphorylated angiotensin II respect the non phosphorylated 
one, preference not shown in the not imprinted polymer. Moreover, the 
material showed a preference for a triply phosphorylated peptide over a 
monophosphorylated one, showing opposite behaviour comparing to TiO2 
material. Of course a more extensive analysis and improvements are needed 
in order to tackle more complex samples.  
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3.4.11 Chemical derivatisation strategies 
The chemical derivatisation strategies exploit the typical properties of the 
phosphate groups in the peptides, like the lability of the phosphoesteric bond 
and the subsequent easy substitution of the phosphate with a nucleophilic 
tag.  
A different widely used approach is the methyl esterification of the carboxylic 
groups, notoriously competitive with the phosphate groups due to their 
negative charge (Fig.2).  
 
3.4.11.1 Methyl esterification of carboxyl-groups  
In IMAC strategy carboxylic groups influence the elution of FPs, due to their 
charge attracted by the positively charged metal of the resin. For this reason 
their esterification could prove useful. Ficarro et al. first applied this strategy 
for the analysis of the cell extract from S.cerevisiae (96) through IMAC 
approach: 383 sites of phosphorylation were detected with this method. 
Some characteristics of this approach have already been depicted in par.4.2 
and will be no further analysed. 
Methyl esterification can be also exploited as a mean of isotopic labeling 
(with CH3OH and CD3OH for two different cellular states) for quantification 
purposes (98). 
 
3.4.11.2 Biotin tagging by β-elimination and Michael addition 
Many chemical derivatisation strategies have been devised to displace the 
phosphoryl group and binding a tag to the “naked” peptide. One of these 
methods (139) relies on the β-elimination of the phosphate from 
phosphoserine and phosphothreonine producing dehydroanaline and β-
aminobutyric acid respectively. These products can be directly detected using 
tandem MS or derivatised, for example by Michael addition of a reactive thiol 
and subsequent binding of a tag. 
One common tag is biotin, notoriously having great affinity for avidin, liable of 
immobilization to an affinity column (140).  
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This technique shows the limits of not being applicable to phosphotyrosine 
containing peptides and of the occurrence of side reactions like tagging of 
non phosphorylated serine. 
Zhou et al. (141) proposed another method of derivatisation applicable to all 
residues, even if it involves many steps and it has not been tested on 
complex samples yet.  
 
Figure 2. Chemical derivatisation methods for phosphorylation capture and analysis.  
A) IMAC suffers of aspecific binding of acidic peptides to the resin. Esterification of 
carboxylic groups with Methanol/HCl is a strategy to overcome this problem. 
B) In presence of a strong base the β-elimination at phosphoserine and 
phosphothreonine produces dehydroanaline and  β-aminobutyric acid. These can be 
derivatised with a thiol through a Michael-like addition and a tag can be added. If the 
tag is biotin, its affinity with avidin can be exploited. 
C) FPs can be derivatised to phosphoramidates after esterification of carboxylic groups. 
If a dendrimer is employed the derivatised peptides can be separated through size-
selective methods. 
D) β-elimination and Michael-like addition of cysteamine converts phosphoserine and 
phosphothreonine in lysine  analogues that specific enzymes leave in the C-
terminus.  
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3.4.11.3 Phosphoramidate conversion 
In 2005 Aebersold’s group proposed a derivatisation procedure based on the 
carboxyl protection through methyl esterification followed by conjugation to a 
soluble polymer with phosphoramidate chemistry (PAC) (124). 
The mixture of peptides is first converted to the corresponding methyl esters. 
In this step two cellular states can also be differentially labeled for 
quantitative analysis. Subsequently, the methylated peptides are combined 
and put to react with EDC, imidazole and a polyamine dendrimer. 
Phosphopeptides are converted in the corresponding phosphoramidates, 
easily separated from the non FPs through size selective methods. FPs are 
recovered with a brief acid hydrolysis and sent to the MS analysis. 
When coupled with pervanadate stimulation and an initial 
antiphosphotyrosine protein precipitation step, this method allowed the 
identification and quantification of all known plus previously unknown 
phosphorylation sites in 97 tyrosine proteins in Jurkat T cells. 
A modification of this method was proposed (123), exploiting the reaction of 
the phosphate groups with cystamine and a reducing agent instead of the 
dendrimer. The –SH group of cystamine reacts with maleimide-activated 
glass beads, immobilizing the FPs on a solid phase. This method allowed the 
identification of 229 FPs in the cytosolic proteome of Drosophila 
melanogaster Kc167 cells without any pre-enrichment step. 
 
3.4.11.4 Conversion to aminoethylcysteine 
Even after a good preconcentration step it is difficult the exact assignation of 
a phosphorylation site, due to the lability of the phosphate group, often lost 
during the backbone fragmentation in a MS collision, and to the intrinsic low 
abundance of phosphorylated peptides. 
To address this problem, Knight et al. (142) devised a derivatisation method 
based on β-elimination and Michael addition of cysteamine to convert 
phosphoserine and phosphothreonine in aminoethylcysteine (Aec) and β-
methylaminoethylcysteine respectively. Due to the resemblance of Aec to 
lysine, the use of proteases that recognize this aminoacid (e.g. Lys-C and 
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lysyl endopeptidase) cleaves proteins leaving it in the C-terminus. The 
system works also with β-methylaminoethylcysteine and permits to identify 
the exact site of phosphorylation.  
The limit of the method is the racemization in the addition step, converting 
only 50% of the phosphoaminoacids in the appropriate enzyme substrate. In 
the case of multiply phosphorylated peptides this fact greatly increases the 
complexity of the peptidic mix arising from the protein.  
 
3.4.12 Comparison of enrichment methods 
From this survey of enrichment methods emerges that no single technique is 
able to tackle the entire phosphoproteome. Some methods work in the 
direction of enriching only some species, like the antibodies for 
phosphotyrosine or the combination β-elimination/ Michael addition selective 
for phosphoserine and phosphothreonine. Other methods, like calcium 
precipitation, SAX, SCX and HILIC, work better as preseparation techniques 
to reduce sample complexity before more specific enrichment methods like 
IMAC, MOAC, SIMAC and PAC.  
Every enrichment technique presents advantages and disadvantages, but 
also different specificities. Usually, MOAC is more specific for 
monophosphorylated peptides, due to the strong affinity for the multiply 
phosphorylated ones, not enough eluted. On the contrary, IMAC is more 
specific for  multiply phosphorylated peptides, but has a low capacity and 
selectivity when used with highly complex samples. The combined 
approaches, like SIMAC, seem to be promising but revelate the necessity of 
a pre-enrichment step (143). 
A systematic comparison of methods was made by Bodenmiller and co-
workers (fig.3). They examined the reproducibility, specificity and efficiency of 
IMAC, PAC and two protocols for TiO2 chromatography: pTiO2 (phthalic acid 
in the loading buffer to quench nonspecific binding) and dhbTiO2 (2,5- 
dihydrobenzoic acid, quencher too) (89). Each method was tested through 
the injection of 1.5 mg of tryptic digest from cytosolic fractions from 
Drosophila melanogaster cells. The authors found a very good reproducibility 
 43 
 
of all the methods, making them suitable for quantitative analysis. Moreover, 
none of the methods was able to reveal the entire phosphoproteome, but 
they show partial overlapping results between each other. 
In general a simple and straightforward strategy is desired, with few 
preparation steps and little sample handling in order to avoid loss of FPs. It is 
of course critical also the amount of starting material and the expertise of the 
people performing the extractions. For this reason detailed protocols are 
needed (144), (66). 
 
Figure 3. Comparison of phosphorylation enrichment methods. The graph shows the 
efficiency and selectivity of IMAC, PAC and TiO2, applied on a tryptic digest of a 
cytosolic protein extract of D.melanogaster cells [Bodenmiller et al., 2007]. In the 
starting material no FPs were detected, while the best selectivity in terms of P vs. 
not-P sites was IMAC. 
 
3.5 MS-based strategies for phosphoproteome analysis 
Mass spectrometry has become the preferential method for peptide and 
protein identification following the separation steps, also in the PTM analysis 
(145).  
The first step of a typical MS analysis consists in the cleavage of a single 
protein or a mixture by using a dedicated enzyme, usually trypsin, which 
preferentially cleaves the peptide bonds after arginin or lysine. Moreover, the 
tryptic fragments’ weight is 700-3500 Da, a size suitable for MS analysis.  
The peptides are thus separated by nanoLC and vaporized/ionized through 
an ESI source. Their mass is evaluated and a second fragmentation, 
generating MS/MS spectra, permits to evaluate also their aminoacidic 
sequence. This is possible because of the higher lability of the bonds 
between aminoacids. Depending on the position of the cleavage along the 
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peptide chain, the MS/MS fragments are classified in a,b,c (starting from the 
N-terminal) or x,y,z (starting from the C-terminal) according to Roepstorff and 
Fohlman (146), (147) (Fig.4). Only the highest abundance peptides are 
submitted to MS/MS. This creates a hurdle in phosphoproteomics, because 
of the lower abundance and difficult ionization of FPs compared to the co-
present not-FPs, thus introducing the need of an enrichment step, as 
explained in section 4. 
The information about the peptide sequence is submitted to database-digging 
softwares as MASCOT (148) or SEQUEST (149), which explore protein 
databases to find a sequence match with previously annotated proteins and 
rank the correlations through a probability score. 
 
Figure 4. Common nomenclature of peptide fragment ions. The peptide fragmentation in 
MS/MS mostly breaks the inter-residue bonds to generate fragment series. CID 
generates preferentially y and b ions, while mostly z and c ions are originated by 
ECD and ETD. Phosphotyrosine immonium ion is diagnostic of tyrosine 
phosphorylation.  
 
3.5.1 Collision Induced Dissociation (CID) 
The most established method to induce a secondary fragmentation in 
peptides is the collision induced dissociation (CID). Basically, the peptide ion 
collides with an inert gas (He or Ar) which transfers its kinetic energy, 
subsequently redistributed between the atoms bringing to the breaking of the 
bonds. When a phosphoserine or phosphothreonine is present in the peptide 
sequence, the phosphoesteric bond is by far the most labile, thus a neutral 
loss of phosphoric acid H3PO4 (98 Da) takes place, originating respectively 
dehydroalanine and dehydroaminobutiric acid. Given that most part of the 
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energy is employed to break the phosphoesteric bond, far less energy is 
available for the subsequent fragmentation of the peptide chain (150).  
This drains information when the identification of the  phosphate group 
position is needed: only the bare presence or absence of a phosphate is 
assessed.  
To overcome this issue several strategies have been applied. The first one is 
the introduction of a tertiary fragmentation, specifically directed towards 
peptides where a phosphate loss is detected. This strategy is named pdMS3 
(phosphorylation directed MS3) (151). The information due to the alternative 
fragmentations of the precursor ion are in this case lost, but they can be kept 
through another approach, named Multi-Stage Activation (MSA) (152). In this 
case the ion trap, filled with the selected ion coming from neutral loss, is filled 
again with the original peptide and both are fragmented at the same time, 
originating a superimposed MS2 / MS3 spectra more information-rich.  
Partial neutral loss happens also on phosphotyrosine residues, which leave a 
HPO3 group (80Da) originating a characteristic phosphotyrosine immonium 
ion at m/z 216 (fig.4). The phosphoesteric bond is however in this case more 
stable, thus not compromising the information collection. Steen et al., for 
example, used the diagnostic fragment at m/z 216 for the selective detection 
of phosphotyrosine-containing peptides in chicken ovalbumin and murine 
MAP-kinase 2 (79). 
 
3.5.2  Electron capture dissociation (ECD) 
The limit of the peptide backbone poor fragmentation in the presence of a 
phosphate group was overcome in 1998 with a new fragmentation strategy. 
Electron Capture Dissociation (ECD) is a method developed by Zubarev and 
colleagues to improve the fragmentation of multiply charged protein and 
peptide ions (153). These ions capture easily a thermal electron (<0.2 eV), 
which induces a non ergodic fragmentation, i.e. without vibrational energy 
redistribution like in CID. The result is a fragmentation mostly at S-S and N-
Cα backbone bonds, leaving intact the PTM bonds. The generated ions are c 
and z type (fig.4) (154). The method has some drawbacks, like a bigger 
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affinity for disulphide bonds and a difficult fragmentation of N-terminal proline, 
which has two bonds to break. Moreover it can be carried out only with 
expensive FT-ICR instruments (up to 1$ million) to generate the static 
magnetic field for the electrons, which reduces its wide scale diffusion. 
 
3.5.3  Electron transfer dissociation (ETD) 
The efforts to find an ECD-like method without the need of expensive 
instruments brought to the advent of ETD (Electron Transfer Dissociation). In 
this approach the electron is transferred to multiply charged peptides (charge 
>2+) through a radical anion with low electron affinity, like anthracene or 
azobenzene (155). The method can be implemented on linear quadrupole 
ITs, with the natural drawback of a reduced resolution and accuracy (156). 
Molina et al. (158) carried out a large scale analysis of human embryonic 
kidney 293T cells, identifying 1435 phosphosites, 80% of which were novel. 
Moreover, they identified 60% more FPs with ETD compared to CID, mainly 
due to the 40% more fragment ions . It has to be remarked the little overlap 
between the two fragmentation techniques, that was exploited to develop an 
integrated approach. Since ETD works better with high charge peptides, Lys-
C was thought to give better results than trypsin, cleaving the peptides only at 
C-terminal lysine. Surprisingly the results did not match the expectations, 
probably due to the high number of missed cleavages in the tryptic lysate 
(157). Another way to generate highly charged peptides was attempted by 
Larsen et al, who added 0.1% m-nitrobenzyl alcohol (m-NBA) to the LC-MS 
solvent (158). This approach increased the predominant charge from 2+ to 
3+, improving the ETD results. The approach is currently being tested on 
more complex samples. Another fact to remark is the evolution of the 
software, born for the CID approach, in the direction of meeting the features 
of spectra generated by new enzymes and fragmentations (159), 
(http://www.matrixscience.com). 
  
 47 
 
Table 2. Comparison of fragmentation methods. All the methods show good results with a 
class of peptides, suggesting that an integrated approach CID/ECD or CID/ETD 
could be more effective [Molina et al., 2007]. 
 
 
Fragmentation 
agent 
Generated 
ions 
Instruments Pros  Cons 
CID 
Inert gas  
(He, Ar) 
y, b ESI-MS 
Better fragmentation 
of low charge 
peptides (2+) 
Fragmentation 
mostly at the 
phosphogroup 
ECD Thermal electron z, c FT-ICR 
Fragmentation only 
along the peptide 
bond 
Need of 
expensive FT-
ICR 
ETD 
Low electron 
affinity anion 
(e.g.anthracene) 
z, c IT, Q-TOF 
Fragmentation only 
along the peptide 
bond 
Less sensitive 
than CID  
 
3.6 Quantitative approaches for phosphoproteome analysis 
In order to take a dynamic picture of the phosphorylation events in a 
particular pathway, it is desirable monitoring which sites are phosphorylated 
and to which extent following a stimulus. To achieve this goal some 
quantification methods are available and can be classified on the basis of the 
analysis step in which the quantitative information is generated: a differential 
isotopic label can be introduced in the cell culture, e.g. with labeled 
aminoacids (SILAC), in the protein mixture (ICAT), in the enzymatic digestion 
(18O labeled water), or in the peptide mixture (iTRAQ), otherwise, in label-free 
experiments, the quantitative information is extracted at the MS level (Fig.7). 
A thorough review about quantitation strategies has been published by 
Bantscheff et al. (160). 
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Figure 7. Strategies for quantitative analysis of protein phosphorylation. An isotopic label 
can be introduced in different moments of the analysis or not at all, in label-free 
experiments. 
 
3.6.1 Metabolic labeling 
Metabolic labeling was first described in 1999 (161). In 2002 Mann and 
coworkers introduced the term Stable Isotope Labeling by Aminoacids in Cell 
culture (SILAC) and used it for quantitative analysis of protein 
phosphorylation in 2003 (162). The typical experiment consists of growing a 
cell population in a medium containing an essential aminoacid labeled with a 
stable isotope (15N or 13C), and growing in parallel another cell population in a 
medium on non-labeled aminoacid. Usually labeled arginine and lysine are 
used, in order to ensure that every peptide from one culture contains a label 
after tryptic digestion. After several doublings, the cells are harvested from 
both cultures, and the protein extracts mixed together. After proteolysis, 
peptides can be analysed by MS and differences in the abundance of a 
peptide in the two cell extracts are shown through the different heights of two 
mass shifted peaks.  
Recently, with this method Olsen et al. (118) reported the most 
comprehensive analysis of the effects of EGF stimulation on 
phosphoproteome dynamics in HeLa cells. This strategy has allowed the 
drawing of some detailed maps of time-resolved signaling pathways (163), 
(164). The major limitation of SILAC stays in the cost of labeled aminoacids. 
  
LEVEL
CELL PROTEINS PEPTIDES MS
METHOD SILAC X
18O X
ICAT X X
iTRAQ X
LABEL-free X
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3.6.2 Protein and peptide labeling 
Post-biosynthetic labeling of proteins and peptides is performed by chemical 
or enzymatic derivatization in vitro.  
Enzymatic labeling exploits the incorporation of 18O atoms from marked water 
during protein digestion. Trypsin and Glu-C introduce two heavy oxygen 
atoms, resulting in a 4 Da mass shift, generally sufficient for the 
differentiation of isotopomers. This method has been applied for quantitative 
proteomic purposes (165), but complete labeling is difficult to obtain. 
Chemical modification can be carried out at protein or peptide level 
introducing a tag on a chemically reactive side chain of an aminoacid [Ong et 
al., 2005], in practice only cysteine and lysine are used for this purpose. A 
group of labeling reagents targets the N-terminus and the ε-aminogroup in 
the lysine side chain. They mostly exploit the N-hydroxysuccinimide (NHS) 
chemistry or other active esters and acid anhydrides, like in the Isotope-
Coded Protein Label (ICPL) (166), isotope Tags for Relative and Absolute 
Quantification (iTRAQ) (167), Tandem Mass Tags (TMT) (168) and 
acetic/succinic anhydride (169).  
iTRAQ is a commercially available reagent, allowing to follow the evolution of 
biological systems over multiple time points. It was used, for example, to 
quantify 222 tyrosine phosphorylation sites across seven time points 
following EGF stimulation (170). 
Carboxylic groups of side chains of aspartic and glutamic acid as well as of 
the C-termini of peptidic chains can be isotopically labeled by esterification 
using deuterated alcohols, for example d0 and d3 methanolic HCl (171). 
This reaction is particularly interesting, because the methylation is also a step 
used in the IMAC enrichment method to reduce aspecific binding of acidic 
peptides to the resin (par. 4.2).  
General drawbacks of the chemical derivatization methods are the production 
of not desired side products, that negatively influence the quantification 
results and the cost of some of the mentioned reagents. 
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3.6.3 Absolute quantification using internal standards 
The use of isotope-labeled internal standards in the field of proteomics is 
known with the name AQUA: Absolute QUAntification of proteins (172). 
The simplest protocol requires adding a known amount of a stable isotope-
labeled peptide to the protein digest and in comparing the signal of it in the 
mass spectra respect the other peak areas (173).  
There are some drawbacks with this approach. First of all the high dynamic 
range of concentrations of peptides makes difficult to find an appropriate 
concentration of standard for every analyte; second, it’s likely to find an 
isobaric peptide to our standard in the peptide mixture, therefore limiting its 
specificity. These problems, however, have been addressed with the 
approach called Multiple Reaction Monitoring (MRM) (174) , in which the 
triple quadrupole MS monitors both peptide and its fragments mass during 
the experiment. The combination of retention time, peptide mass and 
fragment mass practically eliminates the ambiguities, extending the dynamic 
range to 4-5 orders of magnitude (175). The real value of the quantification 
through the AQUA approach is naturally biased by the manipulation of 
sample before adding the standard: the amount of protein determined may 
therefore not reflect its actual expression level in the cell. 
 
3.6.4 Label-free quantification 
There are two approaches for label-free quantification of proteins. The first 
one relies on the measure of the area of a MS peak of a peptide related to a 
protein: the increase of this area means also an increased amount of the 
protein. This approach is called eXtracted Ion Chromatogram (XIC), because 
a single ion peak area is extracted from a plot of signal intensities against 
time in the chromatogram (176). Signal intensities of the same peptide in 
different experiments is then compared to extract quantitative information, for 
example the stoichiometry of phosphorylation (177). 
The other approach measures the amount of peptides generated from a 
protein: the more is the amount of a protein the more are the tandem-MS 
generated peptides. Relative quantification is thus achieved by comparing the 
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number of spectra generated from a protein in different experiments. It is 
necessary a normalization, for example depending from the protein mass, 
creating therefore Protein Abundance Indexes (PAIs) (178). The relationship 
between number of peptides observed and protein amount had been found to 
be logarithmic (emPAI), (179). 
 
3.7 Non-MS approaches to elucidate cellular signaling networks 
3.7.1 Antibody-based approaches 
In order to monitor previously identified phosphorylation sites, arrays 
employing phosphospecific antibodies have been used to investigate dozens 
of phosphorylation sites simultaneously (180). The general hurdle of these 
techniques is the limited availability of dedicated antibodies, however further 
improvements could extend the use of microarray technology in 
phosphoprotein studies (181). 
Methods were developed to monitor the phosphorylation status of tyrosine 
(182) and the kinetics of phosphorylation (183) proteins in a multiplex format. 
In order to evaluate the phosphorylation dynamics on a cellular scale, flow 
citometry approaches have been also devised to monitor up to 11 
phosphorylation events in parallel; (184). Again, the main limit of this 
approach is the availability of suitable fluorescent-labeled antibodies. 
 
3.7.2 Interaction of phosphoproteins and phosphorylated sites 
The phosphorylation-related events include also protein-protein interactions 
in the cell signaling network. To investigate these phenomena, Jones et al. 
(185) devised a protein array to study the binary interactions  between 61 
fluorescent-labeled, tyrosine phosphorylated peptides from EGFR receptors 
with approximately 150 SH2 and PTB domains. By measuring the 
fluorescence at different titration points they determined the KD values for 
every peptide-receptor couple.  
Another approach was followed by Yaoi et al. (186), that immobilized SH2 
domains on microspheres to extract interacting proteins and phosphoproteins 
from a complex mixture of different cell lines. 
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Both approaches revealed new insights in the cellular signaling networks. 
 
3.7.3 Kinase screening on peptide and protein arrays 
Peptide microarrays consist of synthetic peptide sequences deposited onto 
glass slides or attached to a derivatised surface, usually in triplicate, with 
peptides having substitutions in the phosphorylation sites as controls. The in 
vitro phosphorylation reaction is performed in the presence of radiolabeled 
ATP, the array exposed to a film and the image captured. The method 
assumes that phosphorylation of peptides should be in most of the cases 
similar to that of the same sequence in the intact protein, due to the fact that 
many phosphorylation sites are in accessible and flexible regions of the 
protein structure (130). Collins et al. used this approach for phosphorylation 
investigation of synaptic proteins, finding 28 unique phosphorylation sites 
(97).  
The in vitro phosphorylation can naturally be different from the in vivo action, 
but the screening can select and give priority to some phosphorylation sites 
for further investigation.   
The same approach can be used for immobilized proteins or protein domains. 
Ptacek et al. (187) immobilized yeast proteins on high density (4400 proteins 
in duplicate) arrays on glass slides. They screened 87 kinases, finding that 
each kinase recognized up to 256 substrates, with a media of 47 substrates 
per kinase. These data allowed the construction of a global kinase-substrate 
interaction network. There is of course a concern about non specific 
phosphorylation, but also the perspective of a high throughput analysis for 
mapping phosphorylation networks. 
 
3.8  Bioinformatics 
The knowledge discovery process in proteomics has been greatly boosted in 
the last years by the introduction of new bioinformatic tools.  
Widely developed phosphoproteomics databases are for example 
PhosphoSite (188) containing around 100,000 non-redundant 
phosphorylation sites (as well as other modifications, given that the cell 
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signaling is not exclusively phosphocentric), and Phosida (189), containing 
temporal phosphorylation data from cell stimulation in time-course 
experiments.  
These databases permit not only the data mining, but also the interpretation 
of the data in the context of biological regulation, diseases, tissues, 
subcellular localization, protein domains, sequences, motifs, etc. 
(http://www.phosphosite.org) 
 
3.9 Conclusion about phosphoproteomics 
Phosphoproteomics is a rapidly growing field, owing this evolution to the 
importance of the protein phosphorylation in many biological processes and 
its alteration in many diseases.  
The analysis is usually performed with MS-based methods, supported by 
enrichment steps at the protein or peptide level. The improvement of MS has 
been enormous, with increase in resolution, mass accuracy, larger dynamic 
range and more sensitivity and speed, driving the progress in this field. 
Of course it must be mentioned also the evolution in bioinformatics, with the 
developing of adequate software for literature mining, prediction algorithms, 
post-analysis annotation and so on. The aim of phosphoproteomics is not 
only to find phosphorylation sites, but also monitor the dynamic of 
phosphorylation following stimuli to characterize completely signaling 
networks. 
Nowadays the phosphoproteome of highly complex samples has been 
tackled (99), (101), but further development of the methods, including of the 
bioinformatic tools to integrate complex databases, is needed for a more 
thorough knowledge of the mechanisms of phosphorylation networks.  
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4 Molecularly Imprinted Polymers 
A relatively recent technique to develop affinity receptors that could find 
interesting applications in prefractionation is the molecular imprinting of 
polymers (MIPs). MIP permits to synthesise materials with entailed 
recognition properties, by exploiting a “template” mediated synthesis, where 
the “template” is a molecule of interest. During the polymerisation functional 
monomers assemble around the template either via reversible covalent 
bonds (190). or via non-covalent interactions such as hydrogen bonds, ionic 
bonds, hydrophobic interactions, van der Waals forces, etc. (191), (192). 
The pre-assembly is further blocked by crosslinking, forming a polymer with 
embedded molecular depressions, or clefts, complementary to the template 
in size, shape and functionality. 
Molecular imprinting of small molecules such as herbicides, metal ions or 
amino acids has been successfully accomplished and numerous papers 
express the potential of such materials as sensors (193), (194), 
chromatography beds (195), (196), synthetic antibodies (197), (198), 
synthetic enzymes (199), (200) or systems for controlled drug release (201), 
(202). These studies demonstrate that imprinted materials might exhibit very 
high selectivity and even enantioselectivity (199). 
 
4.1 MIPs for proteins and peptides 
A particular challenge concerns the development of MIPs to recognize large 
target molecules such as peptides and proteins. The complexity of such a 
process has been attributed to several reasons (203). First of all, large 
molecules are not able to diffuse through the polymeric network, limiting the 
use of crosslinking that proved to be successful in preserving the imprints. 
Second, the relative non-rigidity of proteins and the ease of unfolding may 
lead to the formation of poorly-defined recognition sites. Third, the poor 
solubility of most proteins in organic solvents limits the synthesis conditions.  
Plus, large molecules possess a number of potential binding groups and the 
choice of the functional monomers plays a crucial role to the quality of the 
imprints. In the case of large biomolecules, it was suggested to exploit the 
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biochemical information on the natural receptors of the target proteins, as a 
starting point in the decisional process towards the definition of the monomer 
composition (204).  
To overcome the limitations posed by the complexity of protein structure, it 
has been proposed to  imprint only part of the protein. The short peptide 
sequences selected are called epitopes (205). 
Regarding peptides imprinting, Kempe and Mosbach (206) demonstrated 
chiral separation of small peptide sequences with highly cross-linked MIPs. In 
another study, Kempe (207) developed a MIP able to recognize Z-oxytocin 
peptide, despite the selectivity of rebinding was not remarkable. In a more 
systematic study, carried out by Klein et al. (208), imprinting of tripeptide 
sequences was assayed, with specific binding of approximately 30% for the 
print sequence and much lower binding of other similar sequences. Finally, 
Hart and Shea (209) proposed metal affinity (Ni2+) to histidine terminal groups 
and obtained a quite successful peptide imprinting.  
A different strategy to address the issue of protein imprinting consists of 
surface aided imprinting, which attempts to produce successful imprints by 
depositing the proteins onto a support, thus taking advantages; 1) of the 
orientation of the template, and 2) of the problems linked to template 
entrapment. Proteins have been at first deposited on / immobilised to a solid 
surface and subsequently the polymer has been grown (210), (211), (212).  
A wide choice of supports and materials have been used: polysiloxanes in 
the very early study of Glad et al. (213) demonstrated a successful imprinting 
of glycoprotein transferrin and later Lulka et al. (214) created a MIP for ricin 
onto silica particles. Fluoro-polymer films were prepared by Ratner and co-
workers (215) by radio frequency glow discharge plasma deposition to form 
films around proteins deposited on a mica surface and subsequently coated 
with disaccharide molecules. Bossi et al. (216) coated polystyrene microtiter 
plates with a thin layer of a stable conjugated polymer (aminophenyl boronic 
acid) polymerized in the presence of various protein templates. Rick and 
Chou (217) imprinted proteins in thin layers of aminophenylboronic acid and 
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used micro-calorimetry measurements to assess the enthalpy changes 
associated with the rebinding and the imprinting efficiency.  
To address the issue of the non compatibility of protein to organic solvents, 
some research groups have been working at the imprinting in aqueous 
conditions, thus with water compatible polymers, which ensures solubility and 
conformational stability of the proteins. Despite of the advantages, results are 
still limited. Hjerten and co-workers (218) pioneered the use of lightly 
crosslinked polyacrylamide hydrogels as the polymeric matrix. Hirayama et 
al. (219) incorporated charged functional groups (either positives or 
negatives) in polyacrylamide gels in the attempts to achieve a better 
recognition. Ou et al. (220) combined polyacrylamide simultaneously with two 
functional monomers, methacrylic acid and 2-(dimethylamino)ethyl 
methacrylate.  
As drawback of hydrogel protein imprinting, the amount of protein template 
that remains entrapped in the MIP is generally high, due to diffusional 
limitations and of the collapse of local polymeric environments. In an attempt 
to ameliorate the rigidity of the hydrogel architecture, Gou et al. (221) 
developed a composite material, by insertion of imprinted polyacrylamide gel 
into the pores of chitosan or modified chitosan beads. The results achieved 
on protein and peptide imprinting still need amelioration, if the final goal of 
these materials is to compete with natural receptor systems. MIP methods for 
the selective recognition of specific peptide sequences and/or proteins 
remain a significant challenge.  
 
4.2 MIPs for proteome with particular attention to phosphopeptides 
Of particular interest in the proteome era becomes the MIP for 
phosphopeptide (FP) enrichment prior to proteomic MS analysis.  
The works published deal quite exclusively with the preparation of MIPs for 
inorganic phosphates, and are mostly targeted to agricultural/waste water 
subject (222), (223). Against all odds, recently Sellergren’s group tried to 
develop a MIP-based method for FP enrichment, achieving positive indication 
on its feasibility, but still limited results (224). Most of the papers dealing with 
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phospho-groups converge in assessing the effectiveness of urea and 
thiourea monomers for the capture. 
 
5 Synthesis and characterization of MIP nanoparticles 
selective for peptides containing phosphotyrosine 
The purpose of this research line is to develop a selective material for pTyr-
containing peptides. The application of such material will be primarily as 
alternative to antibodies, largely employed in phosphoproteome analysis to 
selectively enrich in phosphoproteins and/or phosphopeptides a protein or 
peptide mixture. The advantage of MIPs “plastic antibodies” respect to the 
natural ones is their potential much lower cost of production plus resistance 
to harsch conditions (pressure, temperature, basic or acidic pH) and in 
general a higher stability: they can be used in both aqueous and organic 
solvents (190). In perspective, the nano size of MIPs (nanoMIPs) further 
points out their use in vivo to selectively target a phosphorylated epitope, for 
which a suitable plastic antibody has been devised. This opens the exciting 
scenario of diagnostic and therapeutic molecules specifically tailored on the 
target by using itself as a model template. It remains as remarkable example 
of biomimicry the recent report of Kenneth Shea and colleagues, that devised 
a plastic antibody specifically directed against the peptide mellitin, a 
component of the bee venom. These MIP nanoparticles worked in vivo, by 
removing a lethal amount of toxin from the circulation of mice and 
significantly reduce their mortality (191). The first step of the nanoMIP 
synthesis process consists in the optimization of the production method for 
nanoparticles, that should be of suitable size and polydispersity. Their use in 
vivo requires for example an ideal size less than 100nm (similar in size to 
viruses) to penetrate living cells and translocate within the body (192) 
moreover a Polydispersity Index, associated with an homogeneous 
population (see next paragraph), should be ideally less than 0.2 (193), 
(www.malvern.com). In any case a particle size similar to the size of the 
proteins greatly facilitates the diffusion of the protein itself through the matrix, 
reducing the time of analysis (194), (195). The same method of synthesis is 
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subsequently used in presence of the template molecule to create its print in 
the nanoparticle. The molecule is then removed and the left cavities maintain 
the ability to rebind the same molecule due to their size and chemistry 
(functional groups of monomers oriented to compatible groups of the 
template during the polymer synthesis). The imprinted and not imprinted 
nanoparticles are then tested for specificity, selectivity and capacity (see 
Par.5.4). 
Between the different ways of nanoparticles synthesis, photopolymerization 
seemed to be a valuable choice. This method employs a starter triad 
composed of a coloured antenna, a reducer and an oxidizer, that in this case 
were methylene blue (MB), toluensulphinic acid (TSIA) and diphenyliodonium 
chloride (DPIC), as suggested by Righetti et al. (196) (Fig. 8). The described 
mechanism employs MB, activated by the light, to form an excimer with TSIA, 
by which it is reduced. TSIA radical is an active one, while MB radical is 
passive, thus terminates the polymerization chain reaction. The scope of DPI 
is to boost the reaction through MB˙ oxidation to form an active radical Ph
while regenerating MB* (Fig. 8) (197). This method permits to control the 
polymer growth through a light-switch-like mechanism. 
 
 
 
Figure 8. Chemical structures of the three compounds employed as starter triad for the 
photopolymerization process: A) Methylene blue (MB), B) Diphenyliodonium 
chloride (DPI), C) Toluensulphinic acid (TSIA), plus the mechanism of activation: 
a visible-light-induced electron transfer initiation process (197). 
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5.1 Techniques for nanoparticles physical characterization 
The physical characterization of the nanoparticles can be made with a variety 
of different techniques, addressed to understand and control their synthesis 
and applications. Some widely used techniques are Transmission Electron 
Microscopy (TEM), Scanning Electron Microscopy (SEM) and Atomic Force 
Microscopy (AFM), mainly devoted to visualize the particles and thus explore 
their morphology plus other chatracteristics like aggregation. Other 
techniques like X-ray Photoelectron Spectroscopy (XPS) evaluate instead 
surface characteristics like chemical composition or electronic state (198). 
Dynamic Light Scattering (DLS) is another widely used technique that permits 
to assess particle size, particle number and tendence to aggregation (199).  
In this project AFM and DLS were used. 
 
5.1.1  Dynamic Light Scattering  
Dynamic Light Scattering (DLS) is a physical technique employed to 
determine size distribution of particles in solution. The physical phenomenon 
at the basis is Rayleigh scattering, i.e. the diffusion of light in all the directions 
from particles smaller than the wavelength (200). When the light is coherent 
and monochromatic, like a laser, constructive and destructive interference 
happen between the light emitted by the scatterers. This interference 
changes continuously with the time due to Brownian motion of the particles. 
By detecting the light intensity at a certain angle (usually 173° respect to the 
light source) an intensity fluctuation can thus be observed. This fluctuation is 
faster for fast-moving particles, thus depends on the size of the particles, on 
their shape and on temperature and viscosity of the medium. The fluctuation 
is mathematically expressed by the autocorrelation function (Eq. 1): 
 
where g2(q;τ) is the autocorrelation function at a particular wave vector q, and 
delay time τ, and I is the intensity. At short time delays τ the correlation is 
high, meaning that intensity changed very little due to the little motion of the 
particles. At longer time delays the correlation between intensities instead 
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decreases exponentially and depends essentially on the diffusion coefficient 
of the particles (Fig.9).  
 
 
Figure 9. Representation of the principle of Dynamic Light Scattering. Smaller particles give 
quicker fluctuations of a scattered laser light, as evidenced by the correlation 
function (picture taken from: Wikipedia). 
 
Information about the particles can be extracted by fitting the decay of the 
autocorrelation function. Numerical methods are employed for the purpose 
and they are essentially based on assumed size distribution. For example, if 
the sample is monodisperse the decay is fitted well by a simple exponential 
(Eq.2): 
 
where Г is the decay rate. The translational diffusion coefficient can be 
derived from the wave vector q and Г according to Eq.3: 
 
where q is: 
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where λ is the incident laser wavelength, n0 is the refractive index of the 
sample and θ is the angle at which the detector is positioned respect to the 
light source. 
Through the Stokes-Einstein equation (Eq.5) is therefore possible to derive 
the hydrodynamic radius of the particles. 
 
In this equation D is the diffusion coefficient, kB the Boltzmann’s constant, T 
the temperature, η the viscosity of the medium and r the radius of the 
spherical particle. 
In most cases, however, the sample is polydisperse and the autocorrelation 
function is the sum of exponential decays of all the species in solution (Eq.6).  
 
In this case a commonly used mathematical model to describe the system is 
the cumulant method. This model introduces the variance of the system as 
Polydispersity Index (Eq. 7). 
 
where  is the average decay rate and  is the second order 
Polydispersity Index. 
It should be noted that DLS gives information on the hydrodynamic diameter 
of spheric particles, meaning that it models the behavior of irregular shape 
ojects as they were spheres. Moreover the measured size considers also the 
layer of solvent or ions around the particles. This information is therefore 
generally different from what can be measured for example with electronic 
microscopy like TEM, that  “sees” the naked particles (201). 
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5.1.2 Atomic Force Microscopy 
Atomic Force Microscopy (AFM) is an instrument belonging to the class of 
the Scanning Probe Microscopies (SPM). Its resolution power of the order of 
nanometers make it particularly useful in studying nanoparticles, both for 
morphology and interactions with partners. 
It consists of a silicon or silicon nitride cantilever, with a tip of the radius of 
curvature of the order of nanometers (Fig.10). The tip moves along the 
surface to sample all the relievs and depressions. Interactions of the probe 
with the surface are: mechanical contact force, van der Waals forces, 
capillary forces, chemical bonding, electrostatic forces, magnetic forces, 
Casimir forces, solvation forces, etc (202). 
The scanned area is typically in the order of microns. A laser beam impinges 
above the cantilever being reflected and detected by a diode microarray. The 
detected ray of light raises an electric signal, digitized, elaborated and 
transformed in a reconstructed image of the surface (topography) by a 
dedicated software. 
There are basically three ways of profiling a surface: contact mode, non-
contact mode and tapping mode. 
In contact mode the tip passes close to the surface keeping constant the 
interaction between them. The force must be in this case repulsive, in order 
to avoid the snapping in of the tip. 
In non-contact mode there is not contact between the surface and the tip: the 
cantilever oscillates at a frequency slightly higher than its resonance 
frequency with an amplitude of few nanometers (<10nm). The interaction with 
the surface tends to decrease the frequency of oscillation, but a feedback 
loop system keeps it constant by modifying the average distance between tip 
and surface.  
In intermittent contact, or tapping mode, the oscillation has a higher 
amplitude (100-200nm) and the tip intermittently touches the surface. This 
technique is well suited for soft matter, like lipid bilayers. 
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With AFM it is also possible to evaluate interaction forces by binding a ligand 
to the tip and scanning its interaction with a receptor immobilized to the 
surface (203). 
AFM measurements in liquid samples are also possible, thus preserving the 
nature of labile molecules like proteins (204). 
 
 
Figure 10. Representation of how Atomic Force Microscopy works. A nanometric size tip 
moves along a surface surveying relieves and depressions. A laser beam is 
reflected by the upper part of a cantilever that bears the tip and impinges to a 
detector. This information is interpreted by a software that reconstructs the 
surface topology (picture taken from: http://www.nanoatlas.ifs.hr). 
 
5.2 Nanoparticles synthesis  
Different recipes were followed to find the best approach to produce 
nanoparticles of suitable size (diameter ideally less than 100nm) with low PDI 
and high yield in their production.  
A Fmoc-protected phosphotyrosine (Fmoc-pTyr) was used as template, as 
suggested by Sellergren et al. (240).  
Regarding the choice of functional monomers, positively charged monomers 
could be thought as effective for the phosphate group. Their choice is 
however unadviceable because of the bias introduced in imprinting: charged 
monomers are attracted by the charges independently of the molecule 
structure, i.e. the sequence of aminoacids in the case of peptides and/or 
proteins (240). 
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Instead, the functional monomers chosen were 2-hydroxyethyl methacrylate 
(HEMA) and 1,3-diallylurea (DAU), while crosslinkers were N,N’methylene-
bis-acrylamide (BIS) and 1,4-bis(acryloyl)piperazine (BAP).  
HEMA showed good properties in producing hydrogels, and is extensively 
used in commercial products, like contact lenses, for its swelling properties 
(205). The production of a soft polymer like a hydrogel is necessary when 
working with proteins, to permit their internalization in the polymer matrix 
(206). Dyallylurea has similar properties to the suggested monomers for 
phosphotyrosine imprinting, as recently reported by Sellergren et al. (240). 
BIS is a commonly used crosslinker for protein/peptide imprinting and for gel 
electrophoresis matrixes (207), (208). BAP shows instead more mechanical 
characteristics (keeping the shape) respect to BIS, and this is the reason for 
its choice in protein imprinting (209). The synthesis was carried out in two 
solvents. The aqueous solvent was 100mM, pH 8.20 Tris buffer, that does 
not show interference with the binding with pTyr (like a more “physiological” 
PBS) but at the same time largely employed in proteomics (210). 
 
5.3 Bulk synthesis 
Finally, the bulk synthesis (211) out of two recipes, chosen according to AFM 
and DLS results, was carried out. Rebinding experiments were performed on 
this material in order to collect preliminary information in standardized 
conditions before using nanoparticles. The method consists in preparing a 
solid polymer subsequently crushed and sieved to give micron-sized 
particles. 
 
5.4 Functional characterization of MIPs 
Functional characterization of MIPs consists in the assessment of the 
following characteristics:  
capacity: amount of template that can be bound from 1 mg of polymer;  
specificity: affinity of the template for MIP, expressed by the equilibrium 
dissociation constant KD; 
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selectivity: ability of MIP to discriminate between the template and other 
substrates; 
imprinting factor: ratio between the amount of substrate bound from MIP and 
from its not imprinted counterpart (Not Imprinted Polymer, NIP). 
MIPs ability to rebind the template from its solutions can be evaluated as 
follows. A fixed amount of MIP and of NIP is put in contact with increasing 
concentrations of template molecule. After incubation the amount of free 
substrate [A] is evaluated in solution, therefore assessing its amount bound 
to the resin [AB] by subtracting it from the initial amount of substrate [A]i 
(Eq.4). A graph of substrate bound [AB] respect to the ratio [AB]/[A] 
(Scatchard plot, fig.11) permits to evaluate the affinity constant (KD) of the 
substrate for the polymer (Eq.2) and the maxium amount of guest bound (the 
capacity, or the apparent maximum number of binding sites [B]max) given 
respectively by the slope and the intercept of the Scatchard equation (Eq.3). 
In an ideal 1:1 interaction between substrate and homogeneous binding sites 
of the polymer (Eq. 1), KD is defined as follows: 
 
The nature of the binding sites is never uniform and more kinds of guest-
binding sites exist (212). This characteristic is evidenced by a not linear 
graph like fig.11, whose slopes give the value of two KDs. 
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Figure 11. Scatchard plot to estimate the binding nature of the polymer. Two kinds of binding 
sites are evidenced by two different slopes in the graph. 
 
5.5  Materials and methods 
5.5.1 Materials 
Reagents 2-hydroxyethyl methacrylate (HEMA), 1,4-bis(acryloyl)piperazine 
(BAP), toluensulphinic acid (TSIA), diphenyliodonium chloride (DPI) and 
methylene blue (MB) were purchased by Fluka (Steinheim, DE); 1,3 
diallylurea (DAU) was an Aldrich product obtained from Sigma-Aldrich 
(St.Louis, MO, USA); N,N’methylene-bis-acrylamide (BIS) was a BioRad 
product (Hercules, CA, USA).  
 
5.5.2 Small-scale synthesis of the nanoparticles 
The list of recipes related to the synthesised polymers is reported in Table 5 
(Par.5.6.1). Fmoc-protected phosphotyrosine was added in some samples 
with the ratio 1:2 respect to the functional monomer, as suggested by 
Sellergren et al. (240). 
Synthesis was carried out either in 100mM Tris buffer pH 8.20 or in 
acetonitrile/water 9:1 v/v. All synthesis were made in a final volume of 3 mL 
and in 6 mL HPLC vials with silicon reversible cap. Samples were treated 
with an argon flow for 10 min prior to illumination. Irradiation was performed 
with a VIS transilluminator lamp (40W).  
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5.5.3 Dialysis of the nanoparticles 
After the synthesis samples were dialysed straightaway by using a dialysis 
tubing cellulose membrane (Sigma) with cut-off 12000 Da. MilliQ water was 
used as receptor medium. Dialysis took place for 48h with 3 changes of 
solvent. The sample volume/receptor medium ratio was 1:400. 
 
5.5.4 Size analysis of the nanoparticles 
The size of the synthesized nanoparticles was determined by using Dynamic 
Light Scattering (DLS) technique on a Zetasizer Nano ZS instrument 
equipped with 633nm laser light and DTS Ver. 4.10 software package 
(Malvern Instruments Ltd., Worcestershire, UK). All the samples were 
sonicated for 20min prior to analysis and filtered on a 0.45 µm filter to 
eliminate large sedimenting particles. A 180sec equilibration time was 
needed for the sample to reach ambient temperature (25°C) after sonication. 
The mean value of the particle size was calculated from the results of three 
measurements on each sample. The light was collected at a 173° angle 
respect to the incident laser light. Size measurement results are reported in 
table 6 (Par.5.6.2).  
 
5.5.5 Yield of the nanoparticles 
The yield of the synthesis was calculated for the samples, as reported in 
table 3. Ten ml of solution containing nanoparticles were dialysed and freeze 
dried in pre-weighted Falcon polypropylene tubes. Yields were calculated 
respect to the initial amount of monomers. 
 
5.5.6 Atomic force microscopy of the nanoparticles 
AFM measurements were made on four samples produced with four different 
recipes, chosen according to DLS measurements. The best for size and PdI 
recipes were chosen, considering however to not exclude monomers, 
crosslinkers or solvents that could furnish interesting morphological or 
aggregation characteristics. The instrument was an NT-MDT Solver P47H-
PRO AFM. Mica dishes (Ted Pella) were freshly peeled with cellotape before 
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sample deposition. Samples (not dialysed) were sonicated for 5 min, diluted 
1:1 (v:v) with ethanol and 50µl of the mixture was deposited on mica dishes. 
After 5min the dishes were washed through dipping in 0.20μm filtered MilliQ 
water and dried for 20 sec with an air flow. Images were collected at room 
temperature (20°C) in semi-contact mode using NT-MDT NSG11 silicon 
cantilevers with Au backside coating, with a minimal applied force at a scan 
frequency of 0.5-2 Hz with 512 pixel resolution.  
 
5.5.7 Large-scale synthesis of the nanoparticles 
Eight recipes were produced on a larger scale. The recipes were chosen 
according to DLS measurements as explained in paragraph 5.5.6. Moreover 
a choice of variety in monomers, crosslinkers and solvents could offer 
interesting characteristics of rebinding. The recipes chosen are listed in table 
3. The reaction was carried out in borosilicate glass bottles in a final volume 
of 100 mL after argon bubbling for 10 min. Irradiation was performed with a 
VIS transilluminator lamp (40W) under gentle stirring (250rpm).  
 
Table 3. Samples produced on large scale (W=Tris 100mM, pH8.2; A/W=ACN/Water 9:1 
v/v). 
Recipe Monomers % T 
% 
Cm 
Time 
poly
m.  
mmol (mg) 
Cross 
linker 
mmol 
(mg) 
monomer 
mmol  
(mg)  
Fmoc-
pTyr 
solvent 
F HEMA/BIS 1 80 5' 
6.30  
(974) 
1.58  
(206) 
 W 
F+pTyr HEMA/BIS 1 80 5' 
6.30  
(974) 
1.58 
(206) 
0.79 
(382) 
W 
H1 HEMA/BAP 1 67 5' 
4.55 
(884) 
2.27 
(148) 
 W 
H1+pTyr HEMA/BAP 1 67 5' 
4.55 
(884) 
2.27 
(148) 
1.13 
(532) 
W 
L3 HEMA/BIS 0.2 80 18h 
1.26 
(195) 
0.32 
(41) 
 A/W 
L3+pTyr HEMA/BIS 0.2 80 18h 
1.26 
(195) 
0.32 
(41) 
0.16 
(77) 
A/W 
M3 DAU/BIS 0.2 80 18h 
1.26 
(195) 
0.32 
(45) 
 A/W 
M3+pTyr DAU/BIS 0.2 80 18h 
1.26 
(195) 
0.32 
(45) 
0.16 
(77) 
A/W 
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5.5.8 Dialysis of the nanoparticles 
After the synthesis the samples were dialysed straightaway by using a 
dialysis tubing cellulose membrane (Sigma) with cut-off 12000 Da. MilliQ 
water was used as dialysate. Dialysis took place for 96 hours with 12 
changes of solvent. The sample volume/dialysate ratio was 1:50. 
 
5.5.9 Electrodialysis of the nanoparticles 
Dialysed nanoparticles were electrodialysed for 4h with a set current of 500V, 
5.0mA, 1W. Samples were put in a 3500KDa cut-off SpectraPor membrane 
and added of 10mM histidine (Sigma). Anodic buffer was 1L of a 10mM 
histidine solution. After electrodialysis samples were dialysed again for 4h 
against 1L of MilliQ water with the same membrane. 
 
5.5.10 Concentration of the nanoparticles 
Electrodialysed samples were concentrated with Centriprep YM30 centrifugal 
filter devices (30kDa cut-off, Millipore). The applied centrifugal force was 
1500xg for 15min, according to builder instructions. An initial volume of 
100mL was reduced to 10mL. 
 
5.5.11 Yield evaluation of the nanoparticles 
One mL of every concentrated solution, corresponding to 10mL of initial 
nanoparticles solution, was put in previously weighted 6ml HPLC vials to 
quantify the presence of particles. Samples were freeze-dried for 24h and the 
weight measured with a Ohaus Explorer balance. 
 
5.5.12 Standard bulk synthesis 
Two recipes were chosen to produce bulk polymers and perform rebinding 
experiments. This operation was made to have an idea of the binding 
properties of the material in standardized conditions. 
Solvents acetonitrile, methanol and hydrochloric acid, used to clean the 
synthesized polymers from Fmoc-pTyr, unreacted species and pTyr after 
rebinding, were purchased from Carlo Erba (Milano, Italy). 
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A 500 mg of HEMA/BIS 80%C and DAU/BIS 80%C were dissolved in 8mL 
Tris buffer 20mM, pH 8.20 (final total monomers content 6%T) and divided in 
two 6mL HPLC vials to prepare the not imprinted polymers (NIPs, controls).  
A second aliquot was furtherly added of Fmoc-pTyr with a molar ratio 1:2 
respect to the functional monomer to prepare the molecularly imprinted 
polymers (MIPs, see table 4). All the aliquots were subsequently added of 
100µM methylene blue, 50µM diphenyliodonium chloride and 1 mM 
toluensulphinic acid and treated with an argon flow for 5 min prior to 
illumination. Irradiation was performed with a VIS transilluminator lamp 
(40W). An aluminium foil was used to wrap the reaction environment and 
thus illuminate the reactor from every direction. The illumination duration was 
4h for HEMA/BIS and 16h for DAU/BIS. Here following the recipes: 
 
Table 4. Recipes of the synthesized bulk polymers. 
 
 
Monomer 
(mg / µmol) 
Crosslinker 
(mg / µmol) 
Fmoc-pTyr  
(mg / µmol) 
HEMA/BIS (NIP) 87 / 668 413 / 2679  
HEMA/BIS + pTyr (MIP) 87 / 668 413 / 2679 161 / 334 
DAU/BIS (NIP) 93 / 663 407 /2641  
DAU/BIS + pTyr (MIP) 93 / 663 407 / 2641 160 / 331 
 
5.5.13 Polymer cleaning and drying 
After the synthesis the polymer samples were cleaned through a series of 
washing steps to remove the unreacted monomers, initiators and Fmoc-pTyr. 
The solvent used were in order: acetonitrile/water 1:1 v/v, acetonitrile, 
methanol/HCl 0.1M 1:1 v/v.  
The synthesized HEMA/BIS NIP and MIP were put in 50 mL Falcon tubes 
and added of a volume of solvent 4 times the amount of polymer, mixed on 
an orbital rotor and centrifuged at 3000xgx20’, at 25°C. The synthesized 
DAU/BIS NIP and MIP, after the solvent addition, were divided in aliquots in 2 
mL eppendorf tubes, mixed on the orbital rotor for and centrifuged at 
10000xgx20’, at 25°C. This different treatment was needed because 
DAU/BIS MIP could not sedimentate at low speed. The supernatants were 
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then drained, analysed with UV-VIS spectrometry and replaced with fresh 
solvent. The graphs of the cleaning steps are reported in figure 22 and 23. 
Absorbance was measured with an Unicam UV2 UV-VIS spectrometer, at 
wavelength λ=214nm in quartz cuvettes, to evaluate the presence of double 
bonds (not reacted monomers).  
After the cleaning samples were spread on a cellulose paper and left at 
ambient temperature (25°C) for 72h until dryness. The weights of the dry 
polymers are reported in table 10. Yields were calculated respect to the initial 
amount of monomers. 
 
5.5.14 pTyr calibration curve 
In order to evaluate pTyr presence in rebinding experiments two calibration 
curves were made. Firstly pTyr (Sigma) was dissolved in PBS buffer + 0.02% 
Tween-20 at increasing concentrations. The first curve was produced with an 
Unicam UV2 UV-VIS spectrometer, at wavelength λ=272nm in quartz 
cuvettes. The second one was obtained with a Jasco FP8200 
spectrofluorimeter, in quartz cuvettes, at λexc=265nm and λem=297nm. All the 
measurements were made in triplicate.  
 
5.5.15 Rebinding experiments 
After extensive cleaning the polymers were subdued to rebinding 
experiments to evaluate capacity (μg substrate bound by 1mg of polymer) 
and specificity (KD). Due to the limited amount of DAU/BIS polymer, only 
HEMA/BIS polymer was subdued to these measurements. 
Ten mg aliquots of HEMA/BIS NIP and MIP were put in contact with 2 ml of 
increasing concentrations of pTyr and gently shaken on an orbital rotor for 4 
hours. Then the solutions were centrifuged at 10000 x g x 20’ at 25°C. The 
supernatant was drained and filtered on 0.22 microns cellulose membrane to 
eliminate material in suspension. The pTyr concentration was evaluated on 
the initial solutions and on the drained solutions with a Jasco FP8200 
spectrofluorimeter, in quartz cuvettes, at λexc=272nm and λem=297nm. 
Absorbance data from the initial solutions were used to produce a calibration 
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curve, from which concentrations could be calculated. The difference 
between the concentration of the initial solutions and of the same solutions 
left in contact with the polymer gives the amount of pTyr bound to the 
polymer. Then the pTyr bound for mg of polymer was calculated and max 
capacity estimated. 
 
5.5.16 Cleaning after rebinding 
Polymers subdued to rebinding experiments were cleaned through a series of 
passages in Methanol/HCl 0.1M 1:1 solution in ratio 20:1 respect to the 
polymer amount. The presence of pTyr was evaluated through absorbance 
measurements at wavelength 272nm. Cleaning passages were repeated until 
an absorbance < 0.01 was detectable (table 11, figure 25). 
 
5.6  Results and discussion 
5.6.1  Recipes 
Nanoparticles were synthesized modifying the following parameters: type of 
monomers and crosslinkers, polymerization time, initiators amount, stirring, 
molar crosslinker percentage (%Cm), presence of template. 
The samples were synthesized in triplets. Thirty-five different conditions were 
explored, and they are listed in table 5:  
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Table 5. List of polymerization nanoparticles recipes. W= TRIS buffer 100mM, pH8.2; 
A/W=Acetonitrile/Water 9:1 v/v. 
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A1 HEMA/BIS 1 46 100 1 50 5' y W   
A2 HEMA/BIS 1 46 100 1 50 10' y W   
A3 HEMA/BIS 1 46 100 1 50 30' y W   
A4 HEMA/BIS 1 46 100 1 50 60' y W   
C HEMA/BIS 1 46 10 1 50 10' y W   
D HEMA/BIS 1 46 10 0.1 5 10' y W   
B1 HEMA/BIS 1 46 100 1 50 5' n W   
B2 HEMA/BIS 1 46 100 1 50 10' n W   
G HEMA/BAP 1 40 100 1 50 5' y W   
E1 HEMA/BIS 1 72 100 1 50 5' y W   
E2 HEMA/BIS 1 72 100 1 50 10' y W   
H1 HEMA/BAP 1 67 100 1 50 5' y W   
H2 HEMA/BAP 1 67 100 1 50 10' y W   
F HEMA/BIS 1 80 100 1 50 5' y W   
P HEMA/BIS 1 80 100 1 50 5' y W y 
L1 HEMA/BIS 0.2 80 100 1 50 10' y A/W   
L2 HEMA/BIS 0.2 80 100 1 50 60' y A/W   
L3 HEMA/BIS 0.2 80 100 1 50 18h y A/W   
M1 DAU/BIS 0.2 80 100 1 50 10' y A/W   
M2 DAU/BIS 0.2 80 100 1 50 60' y A/W   
M3 DAU/BIS 0.2 80 100 1 50 18h y A/W   
I1 HEMA/BIS 0.2 80 100 1 50 5' y W   
I2 HEMA/BIS 0.2 80 100 1 50 60' y W   
J DAU/BIS 0.2 80 100 1 50 5' y W   
S HEMA/BIS 0.2 80 100 1 50 60' y A/W y 
T DAU/BIS 0.2 80 100 1 50 60' y A/W y 
Q HEMA/BIS 0.2 80 100 1 50 5' y W y 
R DAU/BIS 0.2 80 100 1 50 5' y W y 
N HEMA/BIS 0.1 80 100 1 50 60' y A/W   
O DAU/BIS 0.1 80 100 1 50 60' y A/W   
K DAU/BIS 0.1 80 100 1 50 5' y W   
U HEMA/BIS 0.1 80 100 1 50 60' y A/W y 
V DAU/BIS 0.1 80 100 1 50 60' y A/W y 
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5.6.2  Dynamic Light Scattering analysis 
DLS analysis was performed on the synthesized samples. 
Results are reported in table 6: 
Table 6. DLS results for size (Z average ± standard deviation) and Polydispersion Index 
(PdI).  
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A1 HEMA/BIS 1 46 5' W   72 ± 65 0.9 
A2 HEMA/BIS 1 46 10' W   167 ± 35 0.4 
A3 HEMA/BIS 1 46 30' W   684 ± 100 0.2 
A4 HEMA/BIS 1 46 60' W   313 ± 150 0.3 
C HEMA/BIS 1 46 10' W   174 ± 14 0.4 
D HEMA/BIS 1 46 10' W   105 ± 44 0.6 
B1 HEMA/BIS 1 46 5' W   194 ± 52 0.6 
B2 HEMA/BIS 1 46 10' W   145 ± 47 0.8 
G HEMA/BAP 1 40 5' W   232 ± 43 0.6 
E1 HEMA/BIS 1 72 5' W   155 ± 10 0.7 
E2 HEMA/BIS 1 72 10' W   187 ± 54 0.7 
H1 HEMA/BAP 1 67 5' W   79 ± 29 0.7 
H2 HEMA/BAP 1 67 10' W   113 ± 19 0.4 
F HEMA/BIS 1 80 5' W   163 ± 15 0.3 
P HEMA/BIS 1 80 5' W y 153 ± 12 0.2 
L1 HEMA/BIS 0.2 80 10' A/W   110 ± 7 0.2 
L2 HEMA/BIS 0.2 80 60' A/W   147 ± 2 0.2 
L3 HEMA/BIS 0.2 80 18h A/W   121 ± 2 0.2 
M1 DAU/BIS 0.2 80 10' A/W   211 ± 18 0.3 
M2 DAU/BIS 0.2 80 60' A/W   164 ± 15 0.2 
M3 DAU/BIS 0.2 80 18h A/W   129 ± 4 0.2 
I1 HEMA/BIS 0.2 80 5' W   172 ± 18 0.2 
I2 HEMA/BIS 0.2 80 60' W   192 ± 10 0.3 
J DAU/BIS 0.2 80 5' W   180 ± 62 0.4 
S HEMA/BIS 0.2 80 60' A/W y 174 ± 3 0.1 
T DAU/BIS 0.2 80 60' A/W y 120 ± 10 0.4 
Q HEMA/BIS 0.2 80 5' W y 131 ± 11 0.4 
R DAU/BIS 0.2 80 5' W y 183 ± 17 0.3 
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N HEMA/BIS 0.1 80 60' A/W   208 ± 32 0.2 
O DAU/BIS 0.1 80 60' A/W   239 ± 10 0.2 
K DAU/BIS 0.1 80 5' W   219 ± 24 0.3 
U HEMA/BIS 0.1 80 60' A/W y  245 ± 18 0.2 
V DAU/BIS 0.1 80 60' A/W y 301 ± 10 0.2 
 
Here following the systematic evaluation of the effect of the variation of 
conditions explored in nanoparticles production. 
 
 
Figure 12. nps size modification due to different experimental conditions in recipes 
containing 1% of total monomers (1%T). PdI values are the red numbers above 
the bars. 
 
In figure 12 emerges the tendency to the increase of nps size with a longer 
polymerization time in Tris buffer (first four bars). 
The lowering of initiators content increases the standard deviation and the 
polydispersity of the sample.  
Avoiding of stirring also has an effect on the standard deviation and on 
polydispersity; moreover, the turbidity of the reaction mixture appears earlier 
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when the sample is not stirred (20’ instead of 25’). The inturbidation means a 
size increase above the micron, thus it can be seen with the naked eye. 
The use of a higher crosslinker percentage does not induce size shrink or 
enlargement on HEMA/BIS nps, but it clearly shrinks HEMA/BAP ones, 
probably due to greater mechanical properties. Bis-acryloyl piperazine was 
also shown to provide slightly larger pores in gels (213). In general a higher 
crosslinker amount helps MIP cavities to retain their shape by making the 
structure more rigid and the use of a 80%C composition gave good results 
both for size and polydispersion. 
HEMA/BAP particles, even though smaller than HEMA/BIS ones, have a high 
PdI and batch to batch synthesis is less reproducible. 
Literature reports a controlled size increase through the “post dilution 
method”, by which dilution of the reaction mixture is made just before the 
gelation point to reach a %T lower than critical concentration (194). This 
method could be mimed by using low %T from the beginning or a worse 
solvent, in which particles can precipitate when they reach a size big enough 
to not stay in suspension. 
The initial recipe modified for crosslinker percentage (80%C instead of 
46%C) was thus subjected to the following experimental variations: lower 
%T, solvent change and functional monomer change.  
 
Figure 13. nps size modification due to the variation of total monomers content %T. 
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In figure 13 it is shown the effect of total monomers content on nps size. The 
first part of the figure (blue bars) reports results obtained in Tris buffer at low 
polymerization time, while the second part (green bars) concerns 
experiments made in ACN/W at higher polymerization time. No high 
polymerization time is available for synthesis in Tris buffer because solutions 
get turbid for the same monomer composition, indicating the presence of 
micron-size particles.  
Raising the monomers amount has a slightly shrinking effect on the nps. The 
most interesting fact in using a lower monomer content is however the low 
PdI of the samples, resulting above 0.3 only in 3 recipes on 18 with %T≤0.2 
(table 6). This fact was already observed by Wulff et al., that reported a 
higher molecular weight and polydispersity for hydrogels produced with high 
crosslinking and monomers amount (194). This significant improvement 
suggests the use of a low monomer amount in the progress of the analysis, 
and polydispersity issues will be no further considered. 
The effect of the solvent was subsequently explored (figure 14). ACN/Water 
9:1 v/v was chosen as dispersing media. In order to facilitate the dissolution 
of the reagents, these were firstly added of 1 volume of water, then diluted 
with 9 volumes of acetonitrile.  
 
Figure 14. Effect of the solvent on nps size. 
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The most interesting effect of the use of ACN/Water 9:1 v/v is its property of 
keeping the size of the particles in the nano range, without generating 
turbidity (thus letting particles to grow to the micro range ) as happens in Tris 
buffer, at least at low total monomer amount (less than 1%T). This can be 
possible in virtue of its worse solubilizing properties respect to the growing 
particle, that cannot grow too much in solution before to precipitate (194). 
This is evidenced by the clear aspect of the solutions after 18h (1000 min) of 
reaction and by the stopped nps growth in 10 min, 60 min and 18h of reaction 
(figure 14). A decrease in nps size for longer polymerization time was also 
observed with the use of DAU monomer. This fact can be explained with the 
faster kinetics of DAU in being incorporated in the growing particles: an initial 
fast production of particles consumes the monomers, that remain in lower 
concentration in solution but still in presence of an excess of initiators. The 
next step was thus the exploration of the effect of monomer substitution from 
HEMA to DAU. 
 
 
Figure 15. Comparison of different functional monomers. 
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There is not a high nanoparticle size variation in the use of HEMA and DAU, 
both in Tris buffer and ACN/W for short and long polymerization time. 
Anyway DAU shows a faster polymerization kinetics than HEMA, showing a 
turbidity point (visible particles in the reaction mixture) of 3’ at 1%T and 15’ at 
0.2% in TRIS buffer (HEMA  gives turbidity in 20’ with the first recipe and 
remains transparent for longer than 60’ with the second one). Literature 
reports a generally different kinetics of the different monomers in being 
included in the growing polymer, as well as a different solubility of the 
nanoparticles made with different monomers (214). 
The following step was the study of the effect of the template in the 
polymerizing mixture. The tested recipes are reported in table 7 and the 
results in figure 16. 
 
Table 7. Evaluation of template effect on the size of the nanoparticles. Samples F-O (left 
side of the table) were produced without the template, while  samples P-Q (right 
side of the table) were produced by following the same recipes plus the addition 
of template. 
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F HEMA/BIS 1 80 5' 630 160 W 163 ± 15 0.3 P 80 153 ± 12 0.2 
I1 HEMA/BIS 0.2 80 5' 126 32 W 172 ± 18 0.2 Q 16 131 ± 11 0.4 
J DAU/BIS 0.2 80 5' 126 32 W 180 ± 62 0.4 R 16 183 ± 17 0.3 
L2 HEMA/BIS 0.2 80 60' 126 32 ACN/W 147 ± 2 0.2 S 16 174 ± 3 0.1 
M2 DAU/BIS 0.2 80 60' 126 32 ACN/W 164 ± 15 0.2 T 16 120 ± 10 0.4 
N HEMA/BIS 0.1 80 60' 63 16 ACN/W 208 ± 32 0.2 U 8  245 ± 18 0.2 
O DAU/BIS 0.1 80 60' 63 16 ACN/W 239 ± 10 0.2 V 8 301 ± 10 0.2 
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Figure 16. nps size modification due to the addition of Fmoc-pTyr in molar ratio 1:2 respect 
to the functional monomer. 
 
The presence of pTyr in the polymerizing mixture does not change 
significantly the dimensions of the nanoparticles. This “template effect” is 
instead reported in some other literature examples (215). 
 
5.6.3 Yield evaluation of small-scale synthesized nanoparticles 
Reaction yield was measured for some recipes (Tab. 8). Their choice was 
made in dependence of the size of the nanoparticles and the Polydispersion 
Index. 
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Table 8. Yield of reaction for some chosen recipes. The lyophilized volume corresponds to 
10ml of the initial solution.  
 
R
e
c
ip
e
 
M
o
n
o
m
e
rs
 
%
 T
 
%
C
 m
 
T
im
e
 
p
o
ly
m
e
ri
z
a
ti
o
n
 
S
o
lv
e
n
t 
A
m
o
u
n
t 
(m
g
) 
Y
ie
ld
 %
 
H1 HEMA/BAP 1 67 5' W 2.8 2.8 
F HEMA/BIS 1 80 5' W 2.3 2.3 
L1 HEMA/BIS 0.2 80 10' A/W 0.1 0.5 
L2 HEMA/BIS 0.2 80 60' A/W 0.5 2.5 
L3 HEMA/BIS 0.2 80 18h A/W 1 5 
M1 DAU/BIS 0.2 80 10' A/W 0.9 4.5 
M2 DAU/BIS 0.2 80 60' A/W 0.6 3 
M3 DAU/BIS 0.2 80 18h A/W 1.1 5.5 
I1 HEMA/BIS 0.2 80 5' W 4.1 20.5 
I2 HEMA/BIS 0.2 80 60' W 0.5 2.5 
J DAU/BIS 0.2 80 5' W 0.4 2 
N HEMA/BIS 0.1 80 60' A/W 0.1 0.5 
O DAU/BIS 0.1 80 60' A/W 0.1 1 
K DAU/BIS 0.1 80 5' W 0.1 1 
 
The yield evaluation evidenced a percentage ranging between 0.5% and 
5.5%, with not significant difference between the use of different monomers 
(table 3). The evaluation of the variation in the product amount gave a ± 
1.0mg of uncertainty. 
Recipes H1, F, L3 and M3, evidenced in tab.4, seemed to be the most 
promising to proceed with a large-scale synthesis, with the intention of not 
excluding the use of any monomer or solvent. Recipes I2 and J, even though 
seemly promising, would have required a huge amount of starting material to 
produce enough polymer. Recipe I1 seems to be an experimental deviation 
(error in the synthesis step, because weight measurement on another part of 
the solution gave the same result), in fact a longer polymerization time gave a 
lower amount of product.  
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5.6.4 AFM images 
The four samples chosen to be produced on a larger scale and thus subdued 
to rebinding experiments were analysed by AFM. Images were taken for not 
dialysed samples. Dialysed samples showed no presence of particles on the 
mica surface both with the same immobilization method used for not dialysed 
samples and by doubling the contact time from 5 to 10 min. 
 
Figure 16. AFM images of a sample prepared with the recipe “F” through the procedure  
explained in the section “materials and methods”. The bar on the right side of the 
pictures is the height of the objects expressed in nanometers. 
 
 
Figure 16.1. 50x50μm. 
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Figure 16.2. 20x20μm. 
 
 
Figure 16.3. 5x5μm. 
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Figure 16.4. 1x1μm. 
 
 
Figure 16.5. 150x150nm. 
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Figure 16.6. Increasing magnification of the same sample. 
 
The particles show a flat, irregular shape, with few aggregates present. The 
size range is approximately from 20nm x 2nm (width x height) to 200nm x 
20nm. 
Another immobilization method was tried on the same sample, employing 
NaHCO3 buffer (200mM pH 9.0) 1:1 v/v instead of ethanol. The results are 
visualized in the next pictures. 
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Figure 17. AFM images the same sample (recipe “F”) immobilized on mica dish through 
previous dilution with NaHCO3 buffer (200mM pH 9.0) 1:1 v/v instead of ethanol. 
 
 
Figure 17.1. 5x5μm. 
 
 
Figure 17.2. 2x2μm. 
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Figure 17.3. 1x1μm. 
 
 
Figure 17.4. Increasing magnification. 
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The comparison of the two immobilization methods evidences a tendency to 
aggregation with the use of the basic buffer instead of ethanol. The other 
samples were therefore analysed through immobilization after a 1:1 v/v 
dilution with ethanol.   
 
Figure 18. AFM images of a sample prepared with the recipe “H1” through the procedure 
explained in the section “materials and methods”. 
 
 
Figure 18.1. 50x50μm. 
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Figure 18.2. 20x20μm. 
 
 
Figure 18.3. 10x10μm. 
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Figure 18.4. 10x10μm with semi-contact error mode acquisition, to put in evidence changes 
in altitude. 
 
 
Figure 18.5. 5x5μm. 
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Figure 18.6. 5x5μm with 3D image elaboration. 
 
The particles show a flat shape, with regular distribution on the surface.  
 
Figure 19. AFM images of a sample prepared with the recipe “L3” through the procedure 
explained in the section “materials and methods”. 
 
 
Figure 19.1. 50x50μm. 
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Figure 19.2. 20x20μm. 
 
 
Figure 19.3. 5x5μm. 
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Figure 19.4. 5x5μm with semicontact error acquisition, to put in evidence changes in 
altitude. 
 
 
Figure 19.5. 2x2μm. 
 
The particles show a flat shape, with more aggregates than the samples 
prepared in Tris buffer. Moreover less particles are present, probably due to 
the fact that the particles were initially immersed in ACN/W instead of Tris 
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buffer. This could have hampered the adsorbtion of the particles to the mica 
surface. 
 
Figure 20. AFM images of a sample prepared with the recipe “M3” through the procedure 
explained in the section “materials and methods”.  
 
 
 
Figure 20.1. 50x50μm. 
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Figure 20.2. 20x20μm. 
 
 
Figure 20.3. 5x5μm. 
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Figure 20.4. 5x5μm with semicontact error-mode acquisition. 
 
 
Figure 20.5. 5x5μm with 3D image elaboration. 
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Figure 20.6. 1x1μm.  
 
The particles show a flat shape, similar to what can be observed in the 
sample prepared with recipe “L3”. Few particles are actually present, 
probably due to the fact that the particles were initially immersed in ACN/W 
instead of Tris buffer. This could have hampered the adsorption of the 
particles to the mica surface. 
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Figure 21. Comparison of images from the four samples for different 
magnifications. 
 
 
Figure 21.1. 50 x 50 μm magnification. 
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Figure 21.2. 20 x 20 μm magnification. 
 
 
Figure 21.3. 5 x 5 μm magnification. 
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The general appearance of the nanoparticles is flat, with height 1/10 of the 
width. The size range is approximately from 20nm x 2nm (width x height) to 
200nm x 20nm.  
There is a higher density of particles for samples produced with recipes “F” 
and “H1”. One possible explanation can be the solvent: they are dissolved in 
Tris buffer, while samples “L3” and “M3” in ACN/Water 9:1 v/v. This fact could 
hamper the attachment of the particles to the mica surface. More aggregates 
are present in samples prepared in ACN/W. 
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 Figure 22: Comparison of AFM and DLS data on a sample prepared with recipe “F”. 
 
There is a seemingly comparable size pattern between AFM and DLS data: 
AFM pictures show a general pattern of bigger, evident nanoparticles with 
dimension around 100nm x 7nm (width x height) on a layer of smaller 
particles with dimension around 20nm x 5nm. A similar pattern seems to 
emerge from DLS data, with a detected population apparently splitted in two 
parts: a first one having hydrodynamic diameter of approximately 20nm and a 
second one 80nm.  
 
5.6.5 Yield evaluation of large-scale synthesized nanoparticles 
Here following the assessment of particles presence in concentrated 
samples. The amount of monomer, crosslinker and pTyr indicated in the table 
are the theoretically present in 1mL of sample if all the starting material was 
converted to nanoparticles. The crosslinker content was 80%C (mol/mol) for 
all the recipes. 
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Table 9. Weight of particles in large-scale synthesized samples. 
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F HEMA/BIS 1 97.4 20.6  W 1.0 
F  + Fmoc-pTyr HEMA/BIS 1 97.4 20.6 38.2 W 0.0 
H1 HEMA/BAP 1 88.4 29.6  W 0.3 
H1+ Fmoc-pTyr HEMA/BAP 1 88.4 29.6 53.2 W 0.5 
L3 HEMA/BIS 0.2 19.5 4.1  A/W 0.0 
L3+ Fmoc-pTyr HEMA/BIS 0.2 19.5 4.1 7.7 A/W 0.9 
M3 DAU/BIS 0.2 19.5 4.5  A/W 0.2 
M3+ Fmoc-pTyr DAU/BIS 0.2 19.5 4.5 7.7 A/W 0.3 
 
The results show a proportionally lower amount of material produced on a 
large scale respect to the amount prepared in small scale (from 2 to 10 times 
less). This reduced efficiency could be due to the reduced amount of light 
that reaches the reagents. The glass of a bottle is in fact thicker than the 
glass of a vial and the reagents are in media less exposed to the light due to 
the bigger volume of liquid. 
  
5.6.6 Cleaning of polymers prepared with standard bulk synthesis 
 
Only HEMA/BIS and DAU/BIS in Tris buffer were prepared with a standard 
synthesis method to evaluate binding properties. Here following the graphs of 
the cleaning of the polymers. The cleaning proceeded until there was no 
further decrease of the signal (Abs< 0.05). 
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Figure 22. Cleaning of HEMA/BIS NIP and MIP. 
 
 
Figure 23. Cleaning of DAU/BIS NIP and MIP. 
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After the cleaning samples were dried on a cellulose filter paper for 72h. The 
amount of polymer is reported in table 10 with the corresponding yields:  
 
Table 10. Amount and yield of the polymers prepared with standard bulk synthesis. 
 
 HEMA/BIS MIP HEMA/BIS NIP DAU/BIS MIP DAU/BIS NIP 
Amount (mg) 216 143 43 118 
Yield % 43 29 9 24 
 
The amount of DAU/BIS MIP was not sufficient to perform rebinding 
experiments, that were thus carried out only on HEMA/BIS polymers.   
 
5.6.7  Rebinding experiments  
Here following the calibration curve for pTyr and the graph showing the 
evaluation of pTyr binding properties of HEMA/BIS NIP and MIP. The 
measurements were made in triplicate. 
 
Figure 24. Calibration curve for increasing concentration of pTyr. 
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Figure 25. Saturation curve for increasing concentration of pTyr. 
 
From the graphs it emerges that the MIP polymer has the tendency to have a 
saturation behaviour, while NIP definitely increases the substrate 
incorporation at increasing concentrations. The capacity of the MIP resin 
tends to settle around 3 μg/mg resin. 
 
5.6.8  Cleaning of polymers after rebinding 
Here following the absorbance data and the graph reporting the cleaning 
passages. Absorbance data of NIP and MIP were put together given their 
identical behaviour in pTyr release. 
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Table 11. Absorbance data at 272nm for the cleaning solutions. 
 
 
HEMA/BIS and 
HEMA/BIS + pTyr 
time (h) total time (h) 
MeOH/HCl 1:1 0.33 2 2 
MeOH/HCl 1:1 0.31 1 3 
MeOH/HCl 1:1 0.24 15 18 
MeOH/HCl 1:1 0.16 1 19 
MeOH/HCl 1:1 0.12 1 20 
MeOH/HCl 1:1 0.06 1 21 
MeOH/HCl 1:1 0.04 1 22 
MeOH/HCl 1:1 0.18 15 37 
MeOH/HCl 1:1 0.05 1 38 
MeOH/HCl 1:1 0.003 2 40 
Tris 0.001 2 42 
Tris   final final 
 
 
 
Figure 26. Trend of pTyr amount extracted from the polymers. 
 
Two days were necessary for the complete cleaning of the polymers from the 
substrate pTyr (Abs <0.01). 
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5.6.9 Rebinding after cleaning 
Here following the data and the related graph obtained in the rebinding 
experiments after polymer cleaning. 
 
Table 12. Absorbance data obtained in rebinding experiments. 
 
H/B (NIP) 
μg/ml 
Abs 
Conc 
(μg/ml) 
C Bound 
(μg/ml) 
C Bound 
(μg/mg) 
13 0.039 12 0.71 0.14 
26 0.070 24 1.92 0.38 
52 0.136 49 2.81 0.56 
130 0.337 126 4.33 0.87 
260 0.667 251 8.78 1.76 
 
H/B pTyr (MIP)  
μg/ml 
Abs 
Conc 
(μg/ml) 
C Bound 
(μg/ml) 
C Bound 
(μg/mg) 
13 0.038 12 1.09 0.22 
26 0.076 26 -0.37 -0.07 
52 0.138 50 2.04 0.41 
130 0.344 128 1.67 0.33 
260 0.676 255 5.35 1.07 
 
 
 
Figure 27. Graph reporting the saturation of NIP and MIP polymers. 
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From the graph it can be noted that MIP tends to bind less substrate than 
NIP. The binding capacity after cleaning showed to be much lower than 
before the cleaning, being 6 times less.  
The complete saturation of the polymers could not be reached, anyway 
higher concentrations of substrate would give absorbance values out of the 
range of confidence of the instrument (0.001<Abs<1.0). 
 
6 Conclusion 
A photopolymerization method for the production of MIP nanoparticles was 
here evaluated. 
The method was tested in different conditions, included the use of different 
monomers, crosslinkers and solvents. 
A remarkable result, already reported by Wulff et al. (194), regards the effect 
of a “bad” solvent, that keeps the size of the particles small avoiding their 
continuous growth in solution through precipitation.  
Good results both for size and polydispersity were obtained with the following 
recipe (“F”): HEMA/BIS 1%T, 80%C, MB 100µM, TSIA 1mM, DPI 50μM, 
agitation, 5’ polymerization. Zave was 163±16nm and PdI 0.332±0.101, with 
good reproducibility.  
Good size results were obtained also with the use of BAP as crosslinker (“G” 
recipe: Zave 81±29nm), but paying the price of a higher polydispersity (PdI 
0.756±0.219).  
Lowering the monomers content from 1% to 0.2%  brings  a not expected 
nanoparticles enlargement both in TRIS buffer and acetonitrile/water 9:1 v/v 
(recipes F-I, P-Q, fig.12).  
DAU shows a quicker polymerization kinetics than HEMA in TRIS buffer, 
having a turbidity point of 3’ at 1%T and 15’ at 0.2%T (HEMA does not give 
turbidity for both recipes after 60’). Moreover DAU nanoparticles are in 
general bigger than HEMA ones (fig.13).  
The addition of Fmoc-pTyr does not bring a significant size and 
polydispersion change (recipes F-P, L-S and M-T, fig.15). 
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The yield evaluation evidenced a percentage ranging between 0.5% and 
5.5%, with not significant difference between the use of different monomers 
(table 8).  
HEMA/BIS recipe was produced with a standard bulk synthesis and subdued 
to rebinding experiments. The results show a saturation behavior for the MIP 
and a tendence to accumulate the substrate for the NIP. The binding capacity 
for the MIP was 3μg/mg resin. 
The results can be considered as still preliminary, with the perspective to 
evaluate binding characteristics for other recipes.  
Nevertheless the DLS analysis showed that our method of synthesis is 
effective in the production of particles with size around 100nm, confirmed 
through AFM microscopy. Moreover an interesting result was the low 
polydispersity of the particles, that in many cases was under 0.2. 
AFM showed particles with flattened shape, probably due to the fact that a 
hydrogel is soft and the combined effect of gravity, surface attraction and 
pressure of the tip of the probe lower their height (216). The future 
perspectives of this research line consist in extending the evaluation of the 
binding properties to other recipes. In particular, testing the properties of the 
nanometric format (the four recipes produced on large scale) would give us 
an indication of the possibility of production of a valid alternative material to 
phosphospecific antibodies. 
 110 
 
Chapter 3 
 
DEVELOPMENT OF AN SPR BIOSENSOR FOR  
HEPCIDIN HORMONE 
 
1 Introduction 
Iron homeostasis related disorders have a high incidence in the population. 
Both anemias, in which iron is deficient, affecting at least 500,000,000 people 
in the world, including at least 2-5% of adolescent at every latitude (225), and 
iron overload disorders, as Hereditary Haemocromatosis (HH) are 
widespread. The C282Y allele on the HFE gene, which is mainly linked to 
HH, occurs in the 5-10% of European population (225). It was demonstrated 
that iron homeostasis is regulated by the 25 aminoacid peptide hormone 
Hepcidin (Hepc) and that urinary and blood levels of Hepc are associated 
with dis-regulation of martial metabolism (226). 
Hepcidin regulates iron export from enterocytes and macrophages by binding 
the only known iron export protein, ferroportin (227). It is synthesized in the 
liver as an 84-aminoacid pre-pro-hormone and matured by proteolysis 
through a furin cleavage to generate the biologically active 25-aa peptide 
(Hepc-25) that is secreted into circulation (228). Hepc-25 leaves the body via 
secretion through the kidneys (229). 
In contrast to the serum, where almost exclusively Hepc-25 (2789.4 Da) is 
detectable, urine also contains N-terminally truncated peptides of 22 
aminoacids (Hepc-22; 2436 Da) and 20 aminoacids (Hepc-20; 2191.7 Da) 
(229), (230).  
Structurally, hepcidin shows a secondary amphipathic structure and is 
particularly rich in basic aminoacids that confer a positive charge with an 
isoelectric point of 8.2 (230). The eight cysteine residues contained within 
hepcidin form four disulfide bridges (figure 1) (229). 
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Figure 1. NMR structure of the major form of human hepcidin The amino and carboxy 
termini are labeled as N and C respectively Disulfide bridges are in yellow (This 
research was originally published in Journal of Biological Chemistry Jordan JB, 
Poppe L, Haniu M, Arvedson T, Syed R, Li V, Kohno H, Kim H, Schnier PD, Kim 
H, Schnier PD, Harvey TS, Miranda LP, Cheetham J, Sasu BJ, Journal of 
Biological Chemistry 2009, 284, 24155, 24167 © The American Society for 
Biochemistry and Molecular Biology]. 
 
Because hepcidin levels reveal important clinical information about 
pathological states, measurement of hepcidin in urine or plasma as a 
biomarker may be interesting to apply in clinical practice. 
Despite significant efforts, the development of a robust assay to detect 
hepcidin proved to be problematic. Initially, hepatic hepcidin mRNA 
expression in the liver was successfully used as a marker, but liver biopsies 
are rarely clinically indicated (231). Immunoassays are commercially 
available for prohepcidin (DRG Diagnostics,Marburg, Germany), however, 
the assay does not recognize the biologically active Hepc-25 (232). By 
contrast, the only available immunoassay against Hepc-25 is not widely 
available yet as a commercial product (233), (234), (235). Therefore, several 
groups have developed assays to detect Hepc-25 based on mass 
spectroscopy (236), (230), (238), (239), (240), (241). 
These last techniques have the disadvantage to be quite expensive and 
demanding in terms of sophisticated instrumentations and dedicated staff. 
Moreover, MS methods revealed the presence, in biological fluids, of non-
functional truncated isoforms of Hepc (e.g. Hepc-22 and Hepc-20), which 
complicated even more the interpretation of the most advanced 
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immunological assays. These forms, in fact, are revealed by the 
immunoassays but do not intervene in iron balance regulation (116). 
It can be concluded that, notwithstanding the very last progresses, it is not 
still available a method for blood and urine Hepc measurement having 
characteristics of accuracy, ease of implementation, and large scale 
distribution at fairly low cost. 
De Domenico et al. (242) identified the hepcidin-binding domain (HBD, figure 
2) on ferroportin and showed that a synthetic 20 aminoacid peptide 
corresponding to the HBD recapitulates the characteristics and specificity of 
hepcidin binding to cell-surface ferroportin. They subsequently developed a 
competitive assay to measure hepcidin concentrations in small volumes of 
biological fluids. 
 
 
Figure 2. Predicted topology of ferroportin (Fpn) The structure of Fpn is based on the study 
of Liu et al, 2005 [adapted from ref.108]. We can note the HBD synthetically 
mimed. 
 
Our attempt is to improve the measurement of the hepcidin levels in body 
fluids developing a point-of-care and label-free assay based on the affinity 
between hepcidin and this synthetic peptide. For the purpose we exploited 
the Surface Plasmon Resonance (SPR) technique (see next paragraph) and 
the immobilization of the synthetic ligand on CM5 Biacore chips. These chips 
present a carboxymethyl dextrane matrix on the surface, to which the N-
terminal of HBD can be bound through the use of EDC/NHS chemistry. 
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The sequence of the wild-type HBD is FDCITTGYAYTQGLSGSILS (pI=3.8). 
To increase solubility, the peptide was synthesized with two arginines added 
at the amino and carboxyl termini (pI=10.0). The arginines did not affect the 
specificity, temperature dependence, or affinity of HBD for hepcidin (243). 
The presence of these extremities could favor the binding of hepcidin, freeing 
aminoacids able to link the hormone. We tested the effectiveness of the 
peptide bait linking it to the chip and evaluating the instrumental response to 
different concentrations of hepcidin-25. 
 
2 Surface Plasmon Resonance 
Surface Plasmon Resonance is a biosensing technique widely employed in 
testing the affinity between ligands and analytes. Biosensors can be defined 
as “…devices comprising a biologically sensitive material immobilized in 
intimate contact with a suitable transducing system to convert the 
biochemical signal into a quantifiable and processible electric signal” (244). 
The physical phenomenum at the core of the system is the variation of 
refractive index of a dielectric medium in contact with a metal (245). Usually 
gold is chosen for its better performance and inertness.  
When a linearly polarized beam of light (polarization parallel to the plane of 
incidence) hits the surface of the metal, the radiation is totally reflected if the 
angle of incidence is higher than the critical angle. At a certain angle of 
incidence, called SPR angle (ΘSPR), the component of the wave of light 
parallel to the surface excites the polaritons, waves of electrons along the 
surface of the metal, if their wavelength corresponds to the wavelength of the 
incident light (i.e. there is resonance). In this case an evanescent field is 
generated at the interface between metal and medium. The amplitude of this 
field decays exponentially from the surface and is sensed usually at a 
maximum distance of 100nm from the surface. The SPR angle depends on 
the wavelength, on the metal, on the temperature and on the polarizability of 
the medium at the interface of the metal, strictly connected to its refractive 
index (n) by the Eq 1:  
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where εr is the relative permittivity of the material and µr is its relative 
permeability. 
This absorption is evidenced by a minimum of reflected light that arrives to a 
detector (usually a photodiode array) at the SPR angle (ΘSPR). The 
dependence of ΘSPR from the refractive index of the medium in contact with 
the metal is the principle at the basis of the system. By immobilizing a ligand 
on the surface, for example, the binding events of analytes to the ligand can 
be monitored through the variation of the refractive index, proportional to the 
mass of analyte in proximity to the interface metal/dielectric (Fig.3). 
 
 
 
Figure 3. Representation of the SPR principle. The SPR angle (angle at which the incident 
light is absorbed and not totally reflected) depends on the refractive index of the 
medium in contact with the metal layer on which the light impinges. This refractive 
index is directly proportional to the mass of analyte bound to the metal surface 
(Picture taken from: Wikipedia).    
 
The variation of n is converted in Responsive Units (RU), proportional to the 
mass of analyte. In the case of proteins, these molecules all have a similar n, 
thus a binding event or simply the presence of any protein in proximity of the 
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surface generates a signal proportional to the mass: 1RU corresponds to 
1pg/mm2 of protein. The binding event is actually a dynamic process that is 
expressed by a profile of RU variation, called sensorgram (Fig.4).  
 
 
Figure 4. Typical SPR sensorgram depicting a binding event (picture taken from: Biacore 
website). 
 
When a solution of analyte is injected in the system and arrives to the 
detecting zone, firstly a variation of RU due to the different refractive index of 
the media is sensed: this is called “bulk effect”. 
The binding of the analyte to the surface is subsequently detected, 
generating an increase of the signal that finally reaches a plateau, when a 
dynamic equilibrium occurs. By stopping the injection of analyte a decrease 
of the signal is detected, and this decrease depends on the affinity between 
analyte and ligand. With SPR the strength of interaction between partners, 
one of which is immobilized on the surface, can be evaluated, as explained in 
par.3.4. Kinetic constants can also be measured by fitting the profile of 
binding and detachment (Fig.4).  
Biacore furnishes chips with different matrixes on a golden layer, to meet the 
need of the researchers. For example a carboxymethylated matrix gives good 
performance with proteins by furnishing sites of attachment through 
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EDC/NHS chemistry and by minimizing aspecific binding, a relevant problem 
when SPR technique is used with complex matrixes. 
A commonly used Biacore chip is CM5, with a carboxymethylated highly 
branched matrix able to furnish multiple points of attachment to the ligand 
molecules.  
 
3 Materials and methods 
3.1 Reagents 
CM5 chips were purchased from Biacore (Sweden). Ethanolamine (Eth), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide 
(NHS) were from Sigma Aldrich (UK). Synthetic Hepc-20 and Hepc-25 were 
purchased from AbCam (UK); peptide ligands (HBD 20-mer and RR-HBD-RR 
24-mer) are custom made at Peptide 2.0 (USA). All reagents and solvents 
were used at analytical grade. 
 
3.2 Peptide immobilisation on CM5 chips 
The CM5 chips were activated with the coupling mixture EDC/NHS 
(200mM/50mM) for 75 min (75µl at 10µl/min). The peptide RR-HBD-RR was 
dissolved at concentration of 50µg/mL in 10mM phosphate buffer at pH 7.0 
and flushed for 12 sec at 10 µL/min flow rate. Quenching of reaction was 
performed with 1M Eth at flow rate 10µl/min for 25 min (total volume: 25 µl) 
One channel was kept as reference by injecting only Eth after EDC/NHS 
activation.  
 
3.3 Hepcidin measurements 
Hepcidin-25 was injected simultaneously in three flow channels of the IFC 
(Integrated Microfluidic Cartridge). A fourth channel was kept as reference. 
The signal from this reference channel was subtracted from the RU response 
of the three channels to give the final value of RU. The chosen 
concentrations were: 1, 5, 10, 25, 50, 100 ng/mL. Running buffer was PBS, 
whose flow was kept at 2µl/min.  
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3.4 KD estimation 
An estimation of the affinity between the ligand RR-HBD-RR and hepcidin-25 
was attempted through the use of Biacore Biasimulation software.  
Curve-fitting of the experimental data enables the association and 
dissociation rate constants and the equilibrium dissociation constant to be 
determined. Of the models proposed by Biacore®, the “1:1 binding” model 
was the one that gave the best fit (the lowest χ2). It is the simplest model and 
describes the interaction between an analyte A and a ligand B as:  
(1)    
The association rate ka (in L/(mol s)) corresponding to the number of 
complexes formed per second in a molar solution of HBD and Hepc-25, is 
defined by the formula:  
(2)    
Where [A], [B] and [AB] are the concentrations of A, B and the AB complex 
The dissociation rate constant kd (in s− 1), corresponding to the portion of the 
complex that dissociates in 1 s, is given by the formula: 
(3)    
Association and dissociation actually occur at the same time. Furthermore, 
association is equal to dissociation at equilibrium, resulting in an equilibrium 
dissociation constant of:  
(4)    
A high KD therefore means that there is low affinity between the analyte and 
the ligand. By fitting the analytical expressions of the response R(t) to the R(t) 
curves in RU obtained in real time by the Biacore® system, it is possible to 
deduce these various constants, ka, kd and KD, that characterise the binding 
of the analyte (Hepc-25 or Hepc-20) to the ligand (RR-HBD-RR). 
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4 Results and discussion 
4.1 Immobilization 
The maximum amount of ligand to be bound to a CM5 chips was assessed to 
be 5500 ± 500 RU (1000RU=1ng/mm2). The choice was therefore to keep the 
ligand level around 3000 RU, to permit the analyte to sneak between the 
immobilized ligands avoiding the crowding of them on the chip surface. 
This result was obtained with a 12µl injection at 10µl/min flow (table 1).  
 
Table 1. Immobilized peptide amount in three channels, expressed in RU 
(1000RU=1ng/mm
2
). 
 
 Flow channel 1 Flow channel 2 Flow channel 3 
Peptide (RU) 2800 3700 2250 
 
4.2 Detection 
Increasing amounts of hepcidin-25 and hepcidin-20 were injected, starting 
from 1 ng/mL rising up until 100 ng/mL. The response for the three channels 
is reported in Table 2. In this case a regenerating solution was not used 
during the experiment between the different injections, because the level of 
saturation of the surface was minimal compared to the total amount of 
binding sites available (<5% considering the mass of analyte compared to the 
mass of ligand bound).  
 
4.3 Regeneration 
Different regenerating solutions were tried with the purpose of removing 
bound hepcidin while not spoil or remove the ligand bound on the chip 
surface. Salt solutions were initially considered, with the idea of a “soft” 
regeneration. Increasing concentrations of NaCl were injected, and finally 
NaCl 500mM proved to be effective for the purpose. Other regenerating 
solutions (NaOH 1mM, 10mM glycine pH 2.5) had the drawback of reducing 
significatively the binding capacity of the ligand upon their use.   
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Table 2. Hepcidin concentrations and relative instrumental response. 
 
Hepcidins 
concentration (ng/mL) 
Hepc-25 media 
(RU) 
Hepc-20 media 
(RU) 
1 10 ± 4 5 ± 2 
5 15 ± 3 10 ± 2 
10 21 ± 6 14 ± 3 
25 26 ± 8 16 ± 3 
50 36 ± 9 14 ± 3 
100 67 ± 21 5 ± 2 
 
Graph 1 shows a sensorgram depicting the instrumental response due to 
different concentrations of analyte in a single flow channel. It can be noticed 
the proportionality of slope due to increasing concentrations of analyte. 
Stabilization of baseline was waited after every injection. 
 
 
Graph 1. Instrumental response following sequential injections of hepcidin in one of the 
available channels. 
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The binding curves following the sequential injections of increasing 
concentrations of hepcidin were then superimposed to highlight the 
proportionality of the signal to hepcidin presence (Graph 2). 
 
 
Graph 2. Superimposition of instrumental responses due to increasing concentrations of 
hepcidin-25. 
 
The response of the system to the increasing hepcidin concentration was 
used to produce a calibration curve (Fig.3). 
 
 
Figure 3. Calibration curve related to increasing hepcidin-25 concentrations. 
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The response of the system was linear in the range of concentrations 
evaluated (R2= 0.98). Sensitivity was not excellent (slope=0.54), as it was the 
intermediate precision (average intra-assay CV%=29). The specificity against 
the competitor hepcidin-20 is however good, even though not quantified for 
not having reached a saturation value of concentration. Anyway the response 
for hepcidin-20 at the highest concentration measured (100ng/mL) was 7% 
than the response of hepcidin-25 (Tab.2), and this result is therefore 
encouraging. 
  
4.4 KD estimation 
The evaluation of KD with our data gave us an attempted value of KD of 
50*10-9M, consistent with previously reported data in solution. De Domenico 
et al, in fact, estimated the interaction of RR-HBD-RR with hepcidin to be 
200nM (242). The discrepancy could be explained with the different 
interaction between partners in solution and when a ligand is immobilized on 
a surface (246). 
 
4.5 LLOD estimation 
The Lower Limit Of Detection (LLOD), considered as a signal 3 times the 
standard deviation of the blank (injection of simple buffer), was assessed to 
be 5ng/mL. 
 
5 Conclusion 
The clinical relevance of hepcidin quantification is elevated. Therefore, the 
measure of hepcidin in serum and urine has been standing as a valuable 
parameter for the differential diagnosis of physiopatological states. In iron 
overload syndromes the hepcidin level allowed to draw a diagnostic pre-
genetic scheme for grouping patients (247). Whereas in anaemic patients, a 
hepcidin level threshold was proposed at 129.5 μg/L to distinguish iron 
deficiency in critically ill patients thus targeting to them an appropriate 
therapy (248). After myocardial infarction the levels of hepcidin have been 
observed to increase both in the ischemic and in the remote myocardium; 
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such up-regulation seems specifically associate with hepcidin, as other iron-
regulatory molecules did not show changes, and it was hypothesized to 
correlate with a defense mechanism to reduce iron toxicity and thus to reduce 
the expansion of the infarction (249). Hepcidin expression does correlate with 
inflammation and increase with increased interleukin-6 (IL6) (250) and is 
negatively correlated with erythropoietin as shown in kidney impairment 
patients (251). 
Our results show the ability of the HBD ligand to bind hepcidin-25, indicating 
the possibility of the measurement of the analyte by the use of the SPR 
technique.  
The system showed poor binding for the competitor hepcidin-20, that is 
considered to be an interferent in the measurement of hepcidin-25 with 
ELISA (252). Regarding this aspect our system could therefore have a 
significative advantage.  
SPR is also a rather straightforward technique: once optimized the protocol of 
analysis the measurement could be made from not specialized personnel. 
The system permitted to measure hepcidin in the pato-physiological 
concentration range of 5-100ng/L (1.5-35nM), with LLOD of 5ng/mL (1.5nM). 
This limit is higher compared to c-ELISA (0.01nM) (252)  and similar to MS 
approaches (0.55-1-55nM for SELDI-TOF (116), 0.5nM for WCX-TOF (252), 
0.75nM for MALDI-TOF (253)) but nevertheless can reveal an hepcidin 
deficit, that starts to be pathological at 5nM (233), (254).  
One of the main problems of this technique is to overcome the aspecific 
binding. This is actually the main problem to solve when somebody wants to 
deal with complex matrixes like serum. Some proteins like albumin have an 
overwhelming presence in blood, that can be more than 6 orders of 
magnitude higher than the concentration of disease markers. Its physiological 
concentration is in fact assessed to be 35-50 mg/mL (255), while hepcidin 
concentration was evaluated to be between 5 and 350 ng/mL considering 
both sexes (262). The natural proceeding in the method development could 
therefore be the analysis of serum samples after filtration on a high MW cut-
off membrane. Kobold et al, for example, obtained a recovery of hepcidin 
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between 95 and 100% by filtering serum samples on a 10kDa cut-off 
cellulose acetate membrane (256). 
In conclusion, the system under development here described has the 
potential to permit an easy and straightforward measurement of hepcidin in 
body fluids, a highly desired goal of the scientific community.  
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Chapter 4 
 
GENERAL CONCLUSIONS 
 
Proteomics showed a pivotal role in the process of discovery of new potential 
biomarkers for diseases (286). The methods are quite well established, but 
an improvement at all levels are needed if we want to dig in the subproteome 
(proteins present in picomolar amount). Disease biomarkers are in fact often 
in this range of concentration in body fluids (287). The detection and 
quantification of established biomarkers can also take advantage of 
biosensing techniques, that are emerging as valuable diagnostic tools. Their 
inner potential lays in the possibility of develop the so-called point-of-care 
diagnostics, i.e. directly at the patient’s bedside (288). 
The use proteomics techniques, in particular 2D-PAGE, it has been here 
applied to discover up- or down-regulated proteins in umbilical cord serum 
and amniotic fluids of Intrauterine Growth Restricted (IUGR) foetuses. A total 
of 14 and 11 proteins were found to be modulated in IUGR umbilical cord 
serum and amniotic fluids respectively. In particular, proteins related to blood 
pressure, coagulation, immunity, oxidative stress and iron/copper metabolism 
were found to be involved in the IUGR pathological picture. Proteomics 
furnishes a snapshot of the whole protein complement in a particular stage of 
life and/or in a particular condition. This is however just a first step: the data 
obtained in this study necessitates a further validation on a larger scale and a 
more deepened analysis to shed light in the pathological mechanisms. The 
final goal is in fact to detect diagnostic biomarkers which could help a specific 
and early IUGR diagnosis. 
The improvement of the analysis methods is at the basis of the process of 
biomarkers discovery. Phosphoproteomics is definitely a subject of 
importance to identify deranged mechanisms, being it involved in so many life 
processes like signalling, cell duplication and apoptosis. Altered 
phosphorylation pathways are in fact present in pathologies like cancer, 
neurodegeneration and diabetes (66).  
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A little step was made here in the production of Molecularly Imprinted 
Polymer nanoparticles (nanoMIPs) for the sequestration of 
phosphoproteins/phosphopeptides from complex protein mixtures. The 
challenge in the production of nano-MIPs is in fact to create a valid 
alternative to antibodies, whose cost is nowadays high and stability is low 
(225). The experiments  allowed to definea photoactivated synthesis protocol 
for the production of nanoMIPs and the first experiments to evaluate the 
efficiency of the material towards the binding phosphotyrosine were also 
performed. The loading capacity of thenanoMIPs were assessed. More 
experiments are needed in order to extend the binding experiments to a wide 
range of nanoMIPs compositions (229).  
The field of biosensors is definitely a sparkling one, being published so many 
papers in the recent years. Biosensors can give a boost in the process of 
biomarkers detection, having the potential of miniaturization and thus of being 
employed directly on the patient’s bedside, when not directly implanted under 
the skin (288). An interesting subject for which to devise a biosensor is 
hepcidin, the major regulator of systemic iron homeostasis in mammals. Its 
quantification could be useful in the deepening the knowledge of iron 
unbalance-related diseases, in stratifying patients but also in monitoring a 
disease progression (290).  
The detection and quantification of hepcidin-25 was here attempted with the 
employment of Surface Plasmon Resonance as biosensing technique. A 
protocol for chip preparation was set and a calibration curve in the 
physiopathological range of concentrations was made. Moreover, the affinity 
between hepcidin-25 and its binding domain on ferroportin (HBD) was 
evaluated, assessing the negligible binding of HBD for the competitor 
hepcidin-20. This part of experiments should be considered as preliminary, 
and it has to be extended to the analysis of real samples, with the intention of 
selecting hepcidin as primary analyte to be measured, overcoming the hurdle 
of aspecific binding, in particular of highly abundant proteins of serum, like 
albumin (291). 
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In conclusion, the field of biomarkers discovery and quantification was here 
explored on three research topics. The results obtained are some steps on 
the path. More steps need to be taken in order to deepen our knowledge of 
these subjects in the near future.   
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